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ABSTRACT 
 
BACKGROUND: Despite the availability of effective therapies for the treatment of 
chronic hepatitis C virus (HCV) infection, therapeutic benefits have yet to be 
experienced by patients affected by the disease, including human immunodeficiency 
virus (HIV) infected individuals. The aims of this study were to describe the 
continuum of hepatitis C care among HIV/HCV coinfected patients and identify 
barriers to achieving optimal management outcomes. 
 
DESIGN AND METHODS: We conducted a retrospective analysis of HIV/HCV 
coinfected patients under care at an urban HIV referral clinic, comprising patients 
identified with HCV infection from 2002-2014. Electronic medical records of eligible 
patients were reviewed, capturing demographic and clinical data. Logistic regression 
analyses were used to identify predictors of failing to achieve optimal outcomes along 
key points on the continuum of care. 
 
RESULTS: Of 135 patients in the study, 62% were male, and median age was 56 
years. Predominant racial groups were black (48.9%) and white (32.6%), and 91.8% 
had some form of public insurance. A significant proportion had psychiatric and 
substance abuse comorbidities that impacted treatment candidacy, including 
depression (40%), active alcohol abuse (16.3%), and ongoing illicit drug use (22.2%). 
The majority of patients had HCV genotype 1 disease (1a - 47%, 1b -11.1%), 91.9% 
were on antiretroviral therapy, and 65% had HIV viral loads < 20 copies/ml. 24.4% of 
subjects had cirrhosis, 27% of whom had a history of decompensated disease. The 
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continuum of care showed that of 135 study subjects, 71% were referred for 
treatment, 67% had a treatment evaluation, 36% were eligible for treatment, 21% 
were prescribed treatment, and only 13% achieved post-treatment sustained virologic 
response (SVR). More than half (54%) of patients not referred for HCV treatment 
evaluation were deemed not to be candidates for treatment by their providers. 
Predictors of not being referred for HCV treatment evaluation were female gender 
(odds ratio: 0.240, 95% confidence interval: 0.064 - 0.907, p = 0.035), depression 
(OR: 0.215, CI: 0.057 - 0.812, p = 0.023), and high HIV viral load (for each 1 log 
increase in viral load, OR: .608, CI: 0.373 - 0.992, p = 0.046). Predictors of not being 
prescribed HCV treatment were high HIV viral load (OR: 0.106, 95% CI: 0.025 - 
0.458, p = 0.003), and having an acquired immunodeficiency syndrome (AIDS) 
diagnosis by both CD4 count criteria and history of opportunistic infections (OR: 
0.037, 95% CI: 0.001 - 0.924, p = 0.045). 
 
CONCLUSIONS: The number of patients achieving HCV cure remains suboptimal. 
The benefits of available and effective HCV therapies will not be realized unless 
effective measures are implemented for dealing with barriers to care. More studies are 
needed to explore ways to improve modifiable factors associated with suboptimal 
HCV management outcomes. 
 
 1 
CHAPTER 1: INTRODUCTION 
 




The hepatitis C virus (HCV) is an enveloped, single stranded, positive sense 
RNA virus approximately 55-80nm in size. It is the only member of the Hepacivirus 
genus of Flaviviridae family of viruses. [1] In 1975, it was first shown that the 
majority of cases of transfusion-associated hepatitis were caused by neither hepatitis 
A virus (HAV) nor hepatitis B virus (HBV), the only two known human 
hepatitis viruses at the time. This drew attention to the likelihood of a separate 
etiology. [2] It was nearly a decade and a half later (1989) that the virus responsible 
for most transfusion-associated non-A non-B hepatitis was identified and cloned, and 
named hepatitis C virus (HCV). [2]  
There are six genotypes of HCV, each with subtypes. The genotypes are 
numbered 1 through 6, while the subtypes are designated letters a, b, and c. This 
system of nomenclature for HCV genotypes was first proposed in 1994, as it was 
recognized that the HCV variants may affect disease progression and response to 
treatment. [3] The genetic variation between HCV genotypes is significant, with a 31-
34% variation in their nucleotide sequence and about a 30% variation in amino acid 
sequence. [3]  
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An image of HCV genome is shown below, highlighting the posttranslational 
cleavages that lead to the production of functional HCV proteins. [4] 
 




HCV is a blood-borne virus most commonly transmitted through injection 
drug use (IDU) through the sharing of injection paraphernalia with a carrier of the 
virus, in health care settings due to the reuse or inadequate sterilization of medical 
equipment, especially syringes and needles, and from accidental exposure to infected 
blood. [5] HCV can also be transmitted by other percutaneous methods, such as 
tattoos. [6] Some people acquire the infection through sexual transmission typically in 
persons with high risk behaviors. [2] Vertical transmission (i.e. mother-to-baby) can 
also occur [7]. HCV is not spread by food or water, saliva, respiratory droplets, breast 
feeding, or non-sexual physical contact. [2] While HCV is found in saliva, semen, 
and ascitic fluid, transmission through these secretions is inefficient [8, 9].   
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Approximately 150-200 million people worldwide and 3.2 million people in 
the United States have chronic HCV infection. [10] According to CDC surveillance, 
the incidence rate of HCV infection in the United States peaked in 1992 at 2.4 cases 
per 100,000. [11] Since then, rates have declined by 88% to 0.3 cases per 100,000 in 
2009, amounting to approximately 16,000 new infections per year. [11]  
Data from the National Health and Nutrition Examination Survey (NHANES) 
provide insight into the demographic characteristics of persons with HCV infection in 
the United States. As of 2010, 67.9% of cases were genotype 1 virus, and 22.1% of 
cases were genotype 2 infections. [12] The prevalence of HCV was higher in men 
than women (1.9% vs. 1.1%, p <0.001). [12] The burden of HCV infection in the 
United States occurs disproportionately among those in the birth cohort 1945-1965, as 
greater than two-thirds (70.1%) of prevalent cases were in the 45 years to 65 years old 
group in the 2010 survey. The HCV prevalence in this age group was a respectable 
3.5%, compared to less than 1.5% prevalence in the 40-44 age group and less than 
0.5% prevalence in all other age groups. [12] While there was a decreasing 
prevalence trend among all races from 2001 to 2010, non-Hispanic blacks bear the 
greatest burden of HCV infection in the United States. [12] 
The strongest risk factors for having anti-HCV antibody included being aged 
45 to 65 years old, being born in the United States, having less than a high school 
education, lifetime history of drug use, abnormal alanine aminotransferase levels 
(ALT > 39 U/L) and having antibodies to herpes simplex virus type 2. [12] Race, 
HIV status, service in US military and gender were not predictive of HCV 
seropositivity. [12] 
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Before universal HCV antibody screening of blood donors began in 1992, 
many HCV infections were transmitted through blood, tissue, and organ donation. 
However, over the past two decades, effective medical interviewing and laboratory 
screening of blood donors has eliminated this source of new infections. It is now 
estimated that only 1 in 1 million blood transfusions may transmit HCV. [11]  
While blood donation and hemodialysis centers have effectively implemented 
measures to prevent HCV transmission, such as regular screening and rigorous 
adherence to infection control practices, not all healthcare facilities have lived up to 
this high standard. From 1998 to 2008, there were 16 investigated outbreaks which 
resulted in 275 incident HCV infections. [11] While these outbreaks occurred in a 
variety of nonhospital healthcare settings, almost all were associated with the reuse of 
syringes leading to contamination of medicine vials or intravenous fluids. [11] 
As transfusion-related and health care associated infections have declined, the 
contribution of injection drug users (IDUs) in HCV transmission has concurrently 
increased. Injection drug use remains the strongest risk factor for HCV infection, and 
the prevalence of anti-HCV antibodies amongst those with lifetime drug use is 
37.5% [12]. The CDC estimates that most new cases of HCV infection occur in IDUs. 
The incidence of HCV infection among IDUs can be as high as 40 cases per 100 
person-years, especially among new injectors, with the highest incidence rates 
occurring early after initiation of injection drug use. [11, 12] 
Sexual transmission of HCV used to be controversial. Observational data from 
HCV-serodiscordant partners in long-term monogamous heterosexual relationships 
show only slightly higher rates of HCV infection than the general population, 
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however data obtained from men who have sex with men (MSM) is more compelling. 
[13] Multiple cross-sectional and cohort studies have reported increased HCV 
prevalence among MSM, and have highlighted unprotected anal intercourse, multiple 
sex partners, rough sexual techniques, and coinfection with HIV and other sexually 
transmitted infections (STI) as potential risk factors. [13] 
Vertical transmission is the leading cause of childhood HCV infection. [7, 14] 
The prevalence of pediatric HCV infection varies from 0.05% to 0.36% in developed 
countries and between 1.8% and 5% in the developing world. The rate of vertical 
transmission from mothers with chronic HCV infection to their children is roughly 4 
– 7 %. [7, 14] While universal neonatal screening is controversial, all children born to 
women with anti-HCV antibodies should be checked for HCV infection. [7] Risk 
factors that increase the likelihood of HCV vertical transmission include maternal 
intravenous drug use, elevated HCV viral load, and coinfection with HIV. [7] 
Currently, no clinical intervention has been proven to reduce the risk of vertical 
transmission of HCV. Cesarean section should not be recommended as a procedure to 
prevent vertical transmission, and breastfeeding should not be forbidden. [7] 
 
1.1c) Clinical Course 
 
Infection with HCV can result in both acute and chronic hepatitis. Acute HCV 
infection is usually asymptomatic and rarely causes hepatic failure. [15] Following 
initial infection, approximately 80% of people do not exhibit any symptoms. Those 
who are acutely symptomatic may exhibit fever, fatigue, decreased appetite, nausea, 
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vomiting, abdominal pain, dark urine, grey-colored feces, joint pain and jaundice. [5] 
However, acute HCV typically leads to chronic infection, and 50 to 85 percent of 
cases develop chronic hepatitis, depending on the population and the source of 
infection. [10]  
The high prevalence of chronic infection may be due to the genetic diversity 
of the virus and its tendency toward rapid mutation, allowing HCV to escape immune 
recognition. [10] Host factors also influence rates of spontaneous clearance of HCV. 
One of the most influential factors appears to be certain polymorphisms of a site close 
to the interleukin-28B (IL28B) gene. The C/C type allele, more common in patients 
of European ancestry compared with those of African ancestry, has been associated 
with significantly higher rates of spontaneous HCV clearance than the T/T type allele. 
[16] 
The clinical course of liver disease associated with chronic HCV infection is 
most often slowly progressive. Approximately 20 to 30 percent of chronically 
infected individuals develop cirrhosis over a 20- to 30-year period of time. A 
systematic review of 111 studies analyzing the natural history of chronic HCV 
estimated that the prevalence of cirrhosis 20 years after infection was 16 percent. [17] 
In the United States, chronic HCV is the most common cause of chronic liver disease 
and the most frequent indication for liver transplantation. [10]  
The risk and rate of progression to cirrhosis varies across different patient 
populations, and the disease may not be progressive in all patients. Studies have 
shown that patients who acquire acute hepatitis C from a blood transfusion show no 
increase in all-cause mortality after 25 years of follow up, while patients who present 
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initially with symptomatic chronic hepatitis tend to report a more aggressive course 
with a high risk of cirrhosis, hepatic decompensation, and hepatocellular carcinoma 
(HCC) [10]. 
The complications of chronic HCV infection are mostly confined to patients 
who have developed cirrhosis, although not all patients with cirrhosis develop 
complications. A study of 384 patients with compensated cirrhosis due to HCV found 
that the risk of developing hepatic decompensation was 3.9 percent per year. The 
most common form of decompensation was ascites, followed by bleeding esophageal 
varices, encephalopathy, and jaundice, which is almost always a sign of advanced 
liver disease in patients with chronic HCV. [18] Furthermore, a number of 
extrahepatic disorders have been associated with chronic HCV infection, including 
essential mixed cryoglobulinemia, lymphoma, membranoproliferative 
glomerulonephritis, autoimmune thyroiditis, porphyria cutanea tarda, and lichen 
planus. [19] 
Survival is decreased in persons with chronic HCV. In the aforementioned 
series of 384 patients with compensated cirrhosis, the 3, 5, and 10-year survival rates 
were 96, 91, and 79 percent respectively; once decompensated cirrhosis occurred, the 
five-year survival fell to 50 percent. [18] In 2007, the age-adjusted mortality rate for 
patients with HCV in the United States was 4.6 per 100,000 persons per year, higher 
than that of HIV (4.2 deaths per 100,000 persons per year). [20] 
Although deaths associated with chronic HCV in the United States are more 
likely to be due to end stage liver disease (ESLD) rather than hepatocellular 
carcinoma (HCC), HCV accounts for approximately one-third of HCC cases in the 
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United States. Estimates of the risk of developing HCC for cirrhotic patients with 
chronic HCV have varied from 0 to 3 percent per year. In contrast to hepatitis B virus 
infection, HCC in patients with HCV occurs almost exclusively in those with 
cirrhosis. [10] 
Disease progression in individual patients may be influenced by several host 
factors, including demographics, behavioral comorbidities, and medical 
comorbidities. Faster progression of hepatic fibrosis is associated with male gender, 
non-black race, and acquisition of HCV after age 40. On the other hand, infected 
children have a decreased risk of disease progression. [10] Behavioral factors 
negatively impacting disease progression include alcohol use, daily marijuana use, 
and high levels of dietary cholesterol consumption, while regular coffee consumption 
has been associated with reduced hepatic fibrosis and slower disease progression. [10] 
Medical comorbidities leading to greater risk of development and progression of 
hepatic fibrosis include obesity, diabetes mellitus, insulin resistance, hepatitis B virus 




Because acute HCV infection is usually asymptomatic, early diagnosis of the 
HCV infection is rare. In those people who go on to develop chronic HCV infection, 
the infection often remains undiagnosed, as symptoms may not develop until serious 
liver damage has occurred. [5] 
 9 
Accurate testing to identify chronic HCV infection is important to enable 
patients and providers to make informed decisions about medical care and options for 
treatment, to minimize the risk of transmitting HCV to others, and to inform persons 
who are not currently infected of their status. [21] 
Beginning in 1998, the United States Centers for Disease Control and 
Prevention (CDC) recommended HCV testing for persons with risk factors for HCV 
infection, and in 2012 they endorsed one-time HCV testing for all persons born 
during 1945–1965 regardless of other risk factors. [21] 
HCV infection is diagnosed in 2 steps. First, screening for anti-HCV 
antibodies with a serological test identifies people who have been infected with the 
virus. [5] The main screening test for detecting anti-HCV is the enzyme immunoassay 
(EIA), which has many advantages including ease of use and automation, low cost, 
and low variability. [22] In addition to laboratory-conducted antibody assays, 
alternative point-of-care tests with similar sensitivity and specificity may be utilized. 
The OraQuick HCV Rapid Antibody Test (OraSure Technologies, Bethlehem, 
Pennsylvania), approved by the FDA in 2010, is a rapid assay for fingerstick capillary 
blood, and provides wider testing access in nontraditional clinical sites. [21] 
The qualitative antibody test is reported as either nonreactive (negative) or 
reactive (positive). A nonreactive anti-HCV result indicates that no HCV antibody 
was detected. A reactive result indicates either current HCV infection, past HCV 
infection that has resolved, or may be a false positive result. In low prevalence 
settings like the healthy blood donor population, the number of false positives by 
enzyme immunoassay (EIA) may exceed the number of true positives, and 
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consequently the positive predictive value of the test may fall below 50%. [22] To 
address this concern, supplemental antibody tests such as the recombinant 
immunoblot assay (RIBA) were developed for use in resolving false-positive EIA 
results. [22] In a high-prevalence setting such as a university referral HIV clinic, the 
positive predictive value of EIA is much higher and supplemental testing is usually 
not necessary. [22]  
A reactive anti-HCV result should be followed by nucleic acid testing (NAT) 
for HCV RNA. [21] Detection of HCV RNA indicates current HCV infection. If 
HCV RNA is not detected in a person with a positive antibody test, that indicates 
either past resolved HCV infection or false HCV antibody positivity. [21] Resolved 
HCV infection is not uncommon, as approximately 15–45% of people infected with 
HCV spontaneously clear the infection by a strong immune response without the need 




Given that the hepatic and extrahepatic manifestations of chronic HCV 
infection cause serious morbidity and mortality, patients may be clinically 
asymptomatic as they progress to advanced liver disease, and safe and effective 
treatments are becoming increasingly available, all patients diagnosed with chronic 
HCV infection should be considered for treatment. [23] The patient’s HCV genotype, 
history of prior treatment, comorbidity burden and degree of liver damage are used to 
guide treatment decisions and management of the disease. [23] 
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Those diagnosed with chronic HCV infection should undergo a laboratory test 
to identify the genotype and subtype of HCV in order to guide choice of antiviral 
therapy. The six genotypes of HCV respond differently to treatment, and it is possible 
to be infected with more than one genotype. [5] The most commonly used test 
method of genotyping is the line probe assay (for example, INNO-LiPA HCV II, 
Siemens Healthcare Diagnostics, Erlangen, Germany), which provides genotype and 
subtype. [23] 
Patients should be categorized based on their HCV disease status and 
treatment history, including exposure and response, in order to guide future treatment 
decisions. Patients who have never received any treatment for HCV are called 
“treatment naïve”. Relapsers are patients who had an undetectable HCV viral load at 
the end of a prior attempt at treatment (end of treatment response), but who did not 
achieve a sustained virologic response (SVR), which is defined as negative HCV 
RNA 12-24 weeks after completing treatment. Partial responders are patients who 
achieved at least a hundred fold (2 log10) drop in HCV RNA by week 12 of treatment 
with an interferon-based regimen, but who did not achieve an end of treatment 
response. Null responders are patients who did not achieve at least a ten fold (1 log10) 
reduction in HCV RNA by week 4, or a hundred fold (2 log10) drop in HCV RNA by 
week 12 of treatment with an interferon-based regimen. Partial and null responders 
tend to have lower SVR rates with the same regimen compared with the treatment-
naïve and relapsers. [23] 
Clinicians considering initiating HCV treatment for a patient should conduct a 
thorough evaluation for medical, psychiatric, and social comorbidities that may affect 
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the treatment plan. The workup should include assessment for renal disease, 
cytopenias, thyroid disease, autoimmune disease, HIV coinfection, potential drug-
drug interactions, pregnancy, psychiatric history, and concurrent alcohol and/or drug 
use. [23] 
Assessment of the degree of liver fibrosis is an important part of a treatment 
evaluation for chronic HCV. Fibrosis stage can impact the likelihood of response to 
treatment with interferon-based regimens. [23] The approximate time to development 
of cirrhosis can be estimated, and treatment can be deferred if little or no fibrosis 
progression has occurred over a long interval. [23] Furthermore, patients with 
advanced fibrosis require screening for hepatocellular carcinoma, and patients with 
cirrhosis require screening for development of complications such as esophageal 
varices. [23]  
Liver fibrosis can be assessed by liver biopsy or through a variety of 
noninvasive tests. [5, 23] Liver biopsy has historically been the gold standard for 
assessing fibrosis, but has several limitations. These include sampling error, which 
leads to misinterpretation in 10 to 15 percent of patients, significant inter-observer 
variability in interpretation, expense, invasiveness, and risk of complications. [23] As 
noninvasive markers are becoming more widely available, and as treatment for HCV 
continues to become less toxic and more effective, there is less need to precisely stage 
a patient’s liver disease with biopsy.  
There are several histologic scoring systems for chronic liver disease, many of 
which assess both grade and stage. Grade indicates the activity or degree of 
inflammation, and the stage represents the amount of fibrosis. [24] In all systems, the 
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stages are determined by both the quantity and location of the fibrosis, with the 
formation of septa and nodules as major factors in the transition from one stage to the 
next. [24] The most sensitive system for staging is the Ishak fibrosis score, which has 
seven stages, and can easily be translated to the other scores. [24] Another commonly 
used system is the Metavir score, which has a five-point fibrosis scale: 
 
• F0: No fibrosis 
• F1: Portal fibrosis without septa 
• F2: Few septa 
• F3: Numerous septa without cirrhosis (bridging fibrosis) 
• F4: Cirrhosis 
 
Various noninvasive tests can be very helpful in assessing liver fibrosis, 
including serologic and radiologic tests. The specific tests chosen will depend on 
local availability. To improve predictive ability, scoring systems have been developed 
that combine assays of multiple serologic markers of liver fibrosis. Panels of indirect 
markers of fibrosis, such as the AST to platelet ratio index (APRI) and Fibrosis-4 
(FIB-4) scores, can be calculated from routine laboratory test results. [23] Specialized 
noninvasive diagnostic tests include panels of direct serologic markers of fibrosis, 
such as FibroSpect II, and ultrasound-based transient elastography, such as 
FibroScan. [23]  
Serologic markers of hepatic fibrosis can broadly be categorized as indirect or 
direct. Indirect markers reflect alterations in hepatic function but do not directly 
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reflect extracellular matrix metabolism, while direct markers reflect extracellular 
matrix turnover. [25] Overall, studies of the various panels suggest that they have 
good ability to differentiate patients with significant fibrosis (F2 to F4) from those 
without significant fibrosis (F0 to F1). [26]  
Potential benefits of these noninvasive tests are ease of administration and 
lower cost compared to liver biopsy. Also, they can be repeated over time to monitor 
progress of liver disease. [23] While noninvasive tests are quite reliable for 
diagnosing cirrhosis as well as for excluding the presence of fibrosis, in the 
intermediate stages their reliability is limited, and therefore no single test can match 
the accuracy of liver biopsy in fibrosis quantitation. [27] 
The aspartate aminotransferase (AST) to platelet ratio index, or APRI, is 
based on the AST level and platelet count and is easy to calculate. The APRI is 
calculated using the AST elevation (which is the AST level divided by the upper limit 
of normal for the lab) and the platelet count per mm3 divided by 1000. A meta-
analysis of 40 studies found that for predicting significant fibrosis (F2 to F4), an 
APRI cutoff of 0.7 had a sensitivity of 77 percent and a specificity of 72 percent. [28] 
For predicting cirrhosis (F4), an APRI cutoff of 1.0 had a sensitivity of 76 percent 
and a specificity of 72 percent. [28]. However, accuracy was lower in patients 
coinfected with HIV and HCV. [28] 
The FIB-4 index combines platelet count, ALT, AST, and age. In one study of 
patients with chronic HCV, the FIB-4 index enabled the correct identification of 
patients with severe fibrosis (F3-F4) and cirrhosis with an area under the receiver 
operating characteristic curve of 0.85 (95% CI 0.82-0.89) and 0.91 (95% CI 0.86-
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0.93), respectively. [29] An FIB-4 index <1.45 had a negative predictive value of 
94.7% to exclude severe fibrosis with a sensitivity of 74.3%. [29] An FIB-4 index 
higher than 3.25 had a positive predictive value to confirm the existence of a 
significant fibrosis (F3-F4) of 82.1% with a specificity of 98.2%. [29] 
FibroTest (Biopredictive, Paris, France), also marketed as FibroSure, is 
another panel of indirect serologic markers for liver fibrosis that has primarily been 
studied in patients with hepatitis C. However, as a proprietary test, it has more limited 
access than the above panels which can be calculated from routine laboratory tests. 
FibroTest involves assessment of alpha-2-macroglobulin, alpha-2-globulin 
(haptoglobin), gammaglobulin, apolipoprotein A1, GGT, and total bilirubin, while 
taking into account the patient's age and sex. Results from the individual assays are 
combined and are used to classify patients having mild fibrosis (F0 to F1), significant 
fibrosis (F2 to F4), or indeterminate. The sensitivity for detection of significant 
fibrosis is approximately 60 to 75 and the specificity is approximately 80 to 90 
percent, respectively. [25] In one study, the severity of disease was correctly 
identified as being mild or significant in approximately 46 percent of patients. [30] 
FibroSpect II (Prometheus Laboratories, San Diego, California) is a panel that 
uses a combination of direct serologic markers for liver fibrosis. The panel includes 
assessment of serum hyaluronic acid, tissue inhibitor of metalloproteinase-1 (TIMP-
1), and alpha-2-macroglobulin. The combination of these assays reliably 
differentiates patients with chronic HCV with moderate to severe fibrosis from those 
with no or mild fibrosis. [25] In a validation study with 402 patients with chronic 
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HCV, the panel had a sensitivity of 77 percent and a specificity of 73 percent for 
predicting moderate to severe fibrosis. [31] 
Ultrasound-based transient elastography, marketed as FibroScan (Echosens, 
Paris, France), is the predominant radiographic test for assessing liver fibrosis in 
patients with chronic HCV. Advantages include safety and good inter- and intra-
observer reliability, while disadvantages include the difficulty of obtaining successful 
examinations in obese patients and patients with ascites, and lack of availability in the 
United States. [25] Overall, for diagnosing significant fibrosis (F2-F4), it has an 
estimated sensitivity of 70 percent and an estimated specificity of 84 percent. [32] For 
diagnosing cirrhosis, the sensitivity and specificity are estimated to be 87 and 91 




The goal of hepatitis C treatment is to eradicate HCV RNA by achieving 
sustained virologic response (SVR), defined by the absence of HCV RNA by 
polymerase chain reaction 12-24 weeks after stopping treatment. An SVR is 
associated with a 99 percent chance of being HCV RNA negative during long-term 
follow-up and can therefore be considered cure of the HCV infection. Achievement 
of an SVR has also been associated with improved clinical outcomes. [33] The cure 
rate depends on several factors, including patient and viral characteristics as well as 
the type of treatment given. [5] Regardless of whether or not treatment is prescribed, 
clinicians should recommend to all patients measures to limit HCV-associated disease 
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progression, including avoidance or reduction of alcohol intake and vaccination 
against hepatitis A and B. 
Guidelines for HCV treatment were released jointly by the American 
Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases 
Society of America (IDSA) in 2014. [33] Other notable guidelines include treatment 
recommendations from the European Association for the Study of the Liver (EASL), 
published in 2014, and United Kingdom consensus guidelines, updated in 2014. [33] 
The World Health Organization (WHO) also released guidelines in 2014 intended 
primarily for clinicians and policy-makers in low- and middle-income countries. [33] 
Until recently, the standard treatment for HCV was combination antiviral 
therapy with pegylated interferon and ribavirin, which are effective against all the 
genotypes of hepatitis viruses. Unfortunately, interferon is poorly tolerated in many 
patients, with potentially debilitating side-effects like fatigue, flu-like symptoms 
(fever, headache, muscle aches), and depression. [33] Additionally, ribavirin is highly 
teratogenic, requiring the use of two forms of birth control in men and women of 
child-bearing potential, and patients must be monitored regularly for anemia and 
thrombocytopenia. [33] Management of this regimen is complex, requiring weekly 
injections for 48 weeks, and many patients fail to complete their treatment. [5] 
Furthermore, response rates are generally only 40 to 50 percent. [33] In order to 
optimize administration of a difficult treatment regimen, management decisions 
focused on identifying patients who would be most likely to respond to therapy or 
who were most likely to suffer liver-related morbidity and mortality without 
successful treatment. [23] 
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Recent advances have led to the development of new antiviral drugs for HCV 
treatment, known as oral directly acting antiviral agents (DAAs), which are much 
more effective, safer and better-tolerated than previous therapies. DAAs simplify 
HCV treatment by significantly decreasing treatment duration and monitoring 
requirements, and by increasing cure rates, with many studies reporting rates above 
90 percent [23, 33]. As a wider range of patients are eligible for treatment with DAAs 
compared with previous therapies, the vast majority of patients with chronic HCV 
infection can theoretically be cured with treatment. In spite of this increased 
population of those eligible for HCV treatment, access to the new treatments remains 
problematic for many. Although the production cost of DAAs is low, the initial prices 
set by companies are very high, which has made access to these drugs difficult. [5] 
In care settings where access to DAAs is limited, treatment can be prioritized 
for those who would be most likely to benefit in the near-term, as recommended by 
the joint guidelines from the AASLD and IDSA. [34] The highest priority patients are 
those who are at highest risk of substantial morbidity and mortality from untreated 
HCV infection, namely those with advanced fibrosis or cirrhosis, transplant 
recipients, and those with severe extrahepatic manifestations of HCV infection. [23, 
34] High priority patients include those at high risk of fibrosis progression, such as 
patients with substantial fibrosis (F2 or greater), HIV coinfection, coexisting liver 
disease, and diabetes mellitus. [23, 34] The potential for transmission of HCV is an 
additional consideration that might prioritize treatment. [23, 34] If interferon-free 
DAA regimens are not yet available for a patient, but are expected to be in the near 
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future, the guidelines recommend deferring therapy until that time unless there is a 
compelling reason to initiate treatment earlier. [23] 
Selection of the optimal HCV treatment regimen for a given patient depends 
mainly on HCV genotype, history of prior treatment, potential drug-drug interactions, 
and insurance coverage. For patients with genotype 1 infection, choice of regimen 
may differ between treatment-naïve and treatment-experienced patients. [33] For both 
groups, there are three regimens with comparably high expected efficacy and safety: 
ledipasvir-sofosbuvir, simeprevir plus sofosbuvir, and ombitasvir-paritaprevir-
ritonavir plus dasabuvir with or without ribavirin. [33] Choosing between them 
depends primarily on potential drug-drug interactions and insurance coverage. [33] 
These interferon-free combination regimens have reported SVR rates in excess of 90 
percent for patients with genotype 1 infection, a major achievement as genotype 1 
infection responded poorly to treatment with interferon and ribavirin. [33] 
The first-ever FDA approved HCV single-tablet combination drug regimen, 
Ledipasvir-sofosbuvir regimens results in SVR rates of approximately 95 percent or 
higher with only mild to moderate side effects, most commonly fatigue or headache. 
[33] The duration of ledipasvir-sofosbuvir treatment depends on HCV viral load, 
prior treatment history, and the presence of cirrhosis, and ranges from 8-24 weeks. 
[33] Ombitasvir-paritaprevir-ritonavir plus dasabuvir with or without weight based 
ribavirin also achieves SVR rates of 95 percent of higher. [33] It is especially 
effective for subtype 1b infection, and duration ranges from 12-24 weeks. [33] 
Adverse effects are common but typically mild in severity. Simeprevir plus 
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sofosbuvir for 12-24 weeks is also highly effective, but the data supporting its use are 
more limited than for the previous two regimens. [33] 
In contrast to patients with genotype 1 infection, those with genotype 2 or 3 
infection achieve relatively high SVR rates (65 to 80 percent) with only 24 weeks of 
therapy with interferon and ribavirin. [35] However, many of these patients went 
without treatment due to contraindications as well as patient and provider reluctance 
to initiate a lengthy and highly toxic treatment. [35] For all patients with genotype 2 
and 3 infection, the recommended regimen is sofosbuvir and ribavirin, with duration 
ranging from 12-24 weeks based on genotype, treatment history, and presence of 
cirrhosis. [35] SVR rates with this regimen among these populations range from 83 to 
97 percent. [35] 
Notably, none of the recommended treatment regimens include the first 
generation HCV protease inhibitors boceprevir and telaprevir. While the development 
of these agents led to higher treatment eligibility rates and improved treatment 
outcomes, the newer DAAs are much better tolerated. [36] Boceprevir and telaprevir 
have recently been pulled from the market as they have fallen out of favor with 
providers and patients. [36] 
 To monitor for potential toxicity with interferon-free regimens, complete 
blood count, basic chemistry panel, and liver enzyme and bilirubin levels are 
recommended at weeks 1 to 2, 4, 8, and 12, with more frequent monitoring for 
concerning results or trends. [33, 35] Virologic cure in response to treatment should 
be assessed by checking the viral load at 12 to 24 weeks following the cessation of 
therapy. Patients who achieve SVR who do not have bridging fibrosis or cirrhosis do 
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not require any specific follow-up for their HCV. Patients who fail to achieve an SVR 
should be followed for signs of progression of their liver disease, and patients with 
bridging fibrosis and cirrhosis, regardless of treatment response, require ongoing 
monitoring for hepatocellular carcinoma and other complications of advanced liver 
disease. [33] 
 
1.2) Background: HIV/HCV Coinfection 
 
Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) represent 
two highly prevalent chronic viral infections worldwide and the United States. The 
CDC estimates that there are upwards of 3.2 million Americans living with HCV, and 
upwards of 1.2 million living with HIV/AIDS. [37] The intersection of these two 
epidemics presents special challenges for patients with HIV/HCV coinfection and 
their health care providers. 
The viral kinetics of HCV are altered by concomitant HIV infection. During 
the chronic stage of HCV infection, a relatively stable viral load or “set point” is 
maintained. However, in the setting of HIV coinfection, HCV RNA levels increase 
starting from HIV seroconversion and continue to increase over time compared with 
patients with HCV alone. [38] While increases in the HCV viral load do not affect 
liver disease severity, they do have an impact on HCV treatment response. [38] 
Coinfection with HIV and HCV is common since both infections share similar 
routes of transmission. In the United States, the prevalence of HCV is especially high 
among HIV infected patients (30-35%), and similar rates have been reported in 
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Europe. [38] As the relative efficiency of transmission differs according to route, the 
prevalence of coinfection varies markedly among various risk groups. In one study, 
HCV seroprevalence in HIV-infected injection drug users (IDUs) was 73 percent, and 
in the low-risk group was 4 percent. [39] Compared to patients with HCV and HIV 
monoinfection, coinfection is associated with more severe psychiatric illness, ongoing 
drug use, poverty, homelessness, and incarceration. [40] Additionally, the order in 
which the two infections are acquired tends to differ by transmission route, as IDUs 
typically acquire HCV before HIV infection while men who have sex with men 
(MSM) usually are infected with HIV before they acquire HCV infection. [38]  
The seroprevalence of HCV in HIV-infected MSM in the United States ranges 
from about 4 to 8 percent, higher than the general population (1.8 percent). [38] Data 
suggest that an increased risk of HCV transmission exists among MSM whose 
predominant risk factor is unsafe sex. [38] In recent years, new HCV infections 
appear to be especially common among HIV-infected MSM; HCV transmission may 
be enhanced by mucosal injury and/or concomitant sexually transmitted diseases. [38] 
Among MSM, unprotected anal sex, fisting, group sex, and recreational gamma-
hydroxybutyrate (GHB) use are associated with HCV acquisition. [38] The 
importance of mucosal damage as a risk factor for HCV acquisition was highlighted 
in a report in which 18 of 20 MSM reported either genital ulcerative disease 
(lymphogranuloma venereum, syphilis, or HSV-2) or fisting within the period of 
acute HCV seroconversion. [13] 
Vertical transmission of HCV infection is increased in HIV-coinfected 
mothers. Meta-analyses have shown that the risk of vertical transmission of HCV to 
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children of HCV RNA-positive women was 5.8% for children of HIV-negative 
women and 10.8% for children of HIV-positive women. The study also found that 
maternal HIV coinfection was the most important determinant of vertical 
transmission risk (adjusted odds ratio: 2.56). [41] 
In patients with chronic HCV infection, concomitant HIV infection is 
associated with higher rates of morbidity and mortality related to liver disease. 
[38] HIV/HCV coinfected patients are less likely to clear viral infection, have more 
rapid rates of fibrosis, and have a higher risk of hepatic decompensation compared 
with HCV monoinfected patients. [38] In a large European cohort of coinfected 
patients, liver-related death accounted for 27% of all deaths, on par with AIDS as the 
leading cause of death. [42] Therefore, all HIV-infected individuals should be 
screened for HCV with an anti-HCV antibody test on entry into HIV care. [40]  
While chronic HCV infection increases the risk of hepatotoxicity from 
antiretroviral therapy (ART) for HIV, the clear benefit of ART outweighs the risk of 
liver injury. [38] Studies also support the positive impact of ART on hepatic fibrosis 
progression in HIV/HCV-coinfected patients, and the CCR5 receptor antagonist 
maraviroc may halt or even reverse the progression of hepatic fibrosis. [43, 44] 
Because of the faster progression to advanced liver disease in the setting of 
HIV infection, coinfection is one reason to prioritize a patient for HCV antiviral 
therapy. [36] In ART-naïve HIV/HCV coinfected patients, ART should be initiated 
regardless of CD4 count, with regimen choice taking into account the potential drug-
drug interactions with HCV antiviral therapy if treatment is planned. [36] Treatments 
for HCV and HIV should not be started simultaneously, so that patients can adjust to 
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each regimen sequentially. [40] For patients already on ART, a regimen switch may 
be warranted if some components cannot be used with the planned HCV treatment 
regimen. [36] 
HCV antiviral regimen selection for HIV/HCV coinfected patients is 
generally the same as for HCV monoinfected patients, and coinfected patients with 
preserved immune function should not be thought of as a special population that has 
lower response rates compared with the monoinfected population. [33, 36] Although 
studies with peginterferon and ribavirin therapy showed that HIV/HCV coinfected 
patients had lower response rates compared with HCV monoinfected patients, SVR 
rates with regimens that contain a direct-acting antiviral appear to have comparable 
treatment outcomes. For example, in coinfected patients with genotype 2 or 3 
infection, sofosbuvir based combinations are associated with high cure rates, similar 
to those observed in subjects with HCV monoinfection. [35, 45] 
 Several important drug interactions between ART and HCV antiviral agents 
should be considered when assessing a HIV/HCV coinfected patient for HCV 
treatment. [36] Sofosbuvir can be safely used with most commonly prescribed 
antiretroviral agents. Ledipasvir-sofosbuvir should not be used with the combination 
of elvitegravir, cobicistat, tenofovir, and emtricitabine, and caution is warranted when 
using other tenofovir-containing regimens as it may result in elevated tenofovir 
levels. [36] Ombitasvir-paritaprevir-ritonavir plus dasabuvir (with or 
without ribavirin) should not be used with darunavir, rilpivirine, efavirenz, or 
lopinavir-ritonavir. [36] Significant drug-drug interactions have also been observed 
with simeprevir, which should not be used with HIV protease inhibitors, including 
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ritonavir, or the non-nucleoside reverse transcriptase inhibitors efavirenz and 
nevirapine. [36] 
 
1.3) Problem Statement 
 
While newer DAA based antiviral treatment regimens for the treatment of 
HCV have shown high cure rates in randomized controlled trials (RCTs), cure rates 
may be much lower in real-world community-based practice settings. People with 
chronic HCV infection need to fulfill several steps along a care continuum to achieve 
optimal health outcomes (disease cure). First, persons must be aware of their HCV 
diagnosis and linked to care with a provider who is knowledgeable and willing to 
manage their infection. Once in care, patients should have HCV RNA confirmation 
testing and undergo liver fibrosis staging to help make decisions regarding HCV 
therapy. Lastly, individuals must receive and maintain good adherence to HCV 
treatment to achieve SVR. This HCV treatment cascade, or care continuum, provides 
a framework for monitoring and identifying gaps in care. 
 
1.4) Goals and Objectives 
 
We conducted a cross-sectional survey of HIV-positive patients from the 
Nathan Smith Clinic who have been diagnosed with HCV infection. We characterized 
each patient’s progression along the HCV care continuum, identifying barriers to 
progression at each step, and characterizing each outcome as optimal or suboptimal. 
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We aimed to identify disparities in care related to demographic and clinical 





 Large gaps currently exist between current real-world practice and optimal 
treatment goals for people with HIV and chronic HCV infection, with progression 
along the HCV cascade of care varying widely in different clinical settings and 
among patient groups. The care continuum approach to assessing points of 
engagement and progression along the spectrum of HCV management will enable 
identification of points along the continuum of care where optimal management gaps 
exist, and highlight specific factors contributing to suboptimal patient outcomes. Data 
from the HCV cascade will also help assess for disparities in care among patient 




CHAPTER 2: REVIEW OF THE LITERATURE 
 
2.1) The HCV Care Continuum 
  
 The “care continuum” concept, also known as “cascade of care” and 
“spectrum of engagement in care” was introduced by Gardner et al. in 2011, in order 
to explore the effectiveness of test-and-treat strategies for HIV prevention. The test-
and-treat approach proposes that expanded testing and earlier treatment of HIV 
infection markedly decreases ongoing HIV transmission, stemming the HIV 
epidemic. [46] However, Gardner et al. realized that poor engagement in care for 
HIV-infected individuals would substantially limit the success of such strategies. 
Gardner et al. described engagement in care as being comprised of multiple 
stages: individuals need to know that they are HIV infected, be linked to and retained 
in regular HIV care, and receive and adhere to effective antiretroviral therapy. [46] 
Gardner et al. proposed that understanding the proportion of the HIV-infected 
population that passes through each stage, and the percentage that drops off, is crucial 
for estimating the potential impact of interventions to improve engagement in care. 
[46] In creating this framework to better characterize engagement in care, Gardner et 
al. laid the foundation that has since been adapted for use across various patient 
populations, health care settings, and chronic disease treatment paradigms. 
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The spectrum of engagement in HIV care in the United States is shown below:
 
 
Reprinted from Gardner et al., 2011 [46] 
 
One of the most notable studies to apply the spectrum of engagement in care 
concept to individuals with chronic HCV infection was Kramer et al. in 2012, which 
aimed to explore the effectiveness of HCV treatment in Veterans Administration 
(VA) hospitals nationwide. [47] Using the nationwide VA HCV Clinical Case 
Registry (CCR), Kramer et al. examined a cohort of veterans who had HCV viremia 
between 2000 and 2005, and identified patients who received treatment with 
pegylated interferon (PEG-INF) and ribavirin. [47] The effectiveness of treatment 
was measured as the proportion of patients who achieved SVR in the entire cohort, 
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and among patients who initiated and completed treatment. [47] Kramer et al. 
identified 99,166 patients with HCV viremia. Of those, 11.6% received PEG-INF 
with ribavirin and 6.4% completed treatment. [47] Contraindications were present in 
57.2% of the patients that did not receive treatment. SVR was documented in 39.9% 
and 58.3% of patients who completed treatment; 23.6% and 50.6% of patients who 
initiated treatment; and 3.9% and 11.2% of the entire HCV cohort for genotype 1 or 4 
and 2 or 3, respectively. [47] Overall, only 3.5% of the entire HCV viremic cohort 
had a documented SVR. [47] A major strength of this study was its size, as it remains 
one of the largest studies to examine HCV treatment effectiveness in a community 
practice setting. Another strength was that it was able to characterize the proportion 
of patients with various contraindications to receiving HCV treatment. Some 
limitations of the study are that it did not capture patient-physician interactions, such 
as patients declining treatment or physicians recommending deferred treatment, and 
that the population of the VA system is not representative of the general population, 




Reprinted from Kramer et al., 2012 [47] 
 
In 2014, Yehia et al. performed a systematic review and meta-analysis of 
studies describing the treatment cascade for persons with chronic HCV infection in 
the United States. [48] The analysis included articles published between January 2003 
and July 2013, and studies were excluded if they were conducted outside of the 
United States, did not present original data, only analyzed data collected prior to 
2000, involved a single site, or focused on special populations. [48] Data from each 
included study were extracted into tables stratified by HCV treatment cascade step. 
[48] Overall, 3.5 million people in the United States were estimated to have chronic 
HCV infection, 50% (95% CI 43-57%) were diagnosed and aware of their infection, 
43% (CI 40-47%) had access to outpatient care, 27% (CI 27-28%) had HCV RNA 
confirmed, 17% (CI 16-17%) underwent liver fibrosis staging, 16% (CI 15-16%) 
were prescribed treatment, and 9% (CI 9-10%) achieved SVR. [48] These results 
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confirmed the existence of large gaps between current practice and treatment goals 
for people with chronic HCV infection. While the main analysis focused on non-VA 
studies, a separate analysis was conducted using VA-specific data in order to 
highlight differences between U.S. veteran and non-veteran populations. [48] Among 
chronic HCV-infected veterans in care, the proportion of those who received hepatic 
fibrosis staging by liver biopsy and who were prescribed HCV treatment was 22% 
and 19% lower, respectively, compared to the general population. [48] Similarly, 
among veterans with chronic HCV infection who were prescribed pegylated 
interferon plus ribavirin, a smaller proportion achieved SVR compared to the general 
population (44% vs. 58%). [48] One limitation of this systematic review was the 
relatively small number of studies identified, particularly for earlier steps in the 
cascade. Furthermore, because studies of special populations were excluded, this 
analysis fails to describe certain populations disproportionately affected by chronic 
HCV infection, such as homeless individuals and prisoners. Lastly, estimates for each 
step in the HCV treatment cascade could not be determined by sex, race/ethnicity, 
socioeconomic status, injection drug use, and HIV status, preventing assessment for 
disparities in care, because these data were not available in the included studies. [48] 
 
2.2) The HCV Care Continuum in HIV Coinfected Patients 
 
 Several studies have aimed to characterize the HCV care continuum in those 
with HCV/HIV coinfection. In 2011, Butt et al. compared the rates for 
HCV treatment eligibility among a national cohort of HCV and HIV/HCV 
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coinfected veterans in care from 1998-2003. [49] Overall, HIV/HCV coinfected 
persons were less likely to be evaluated by a gastroenterologist or hepatologist and 
less likely to be eligible for treatment compared with the HCV-monoinfected 
subjects. Of the 27,452 subjects with HCV and 1225 with HIV/HCV coinfection, 
74.0% and 84.6% had indications for therapy and among these, 43.9% of HCV 
monoinfected and 28.4% of HIV/HCV coinfected subjects were eligible 
for treatment. [49] In exploring the conditions that led to treatment ineligibility, Butt 
et al. found that anemia, decompensated liver disease, renal failure, active psychiatric 
disease, and recent drug abuse or dependence were 1.5 to 2 times more prevalent in 
the coinfected group. [49] This analysis was significant for being the first national 
study to evaluate HCV treatment eligibility and directly compare HCV-monoinfected 
and HIV/HCV coinfected persons. Limitations of this study include that it focuses 
only on veterans engaged in the VA healthcare system, and that indications and 
contraindications for HCV treatment have evolved significantly since 2003, 
especially since the introduction of DAAs. 
 The benefit of conducting analyses of large databases is clear, in that 
observations can be made with greater statistical power. However, the limited 
information available in these databases means that certain barriers in the care 
continuum, such as reasons for non-referral for HCV therapy, can be better evaluated 
by studies focused on single care settings. Cachay et al. (2014) conducted a 
retrospective cohort analysis of HIV-infected patients in care at the UCSD Owen 
Clinic from 2008-2012, identifying reasons for not referring for and not initiating 
HCV therapy after completion of HCV treatment staging. [50] Electronic medical 
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records were reviewed to ascertain reasons for not initiating HCV therapy, and 
logistic regression analyses were used to identify factors associated with lack of 
referral for HCV therapy. [50] Of 4725 total HIV-infected patients, 4534 (96%) were 
screened for HCV, 748 (16%) had reactive serum HCV antibodies, and 542 (11%) 
had active HCV infection. Lack of engagement in care was the most important 
predictor of non-referral for HCV therapy (OR: 5.08, 95% CI 3.24-6.97, p <0.00001). 
[50] Other significant predictors included unstable housing (OR: 2.26), AIDS (OR: 
1.83), having a detectable HIV viral load (OR: 1.98) and being non-white (OR: 1.67). 
[50] The most common reason (40%) for not initiating or deferring HCV therapy was 
the presence of ongoing barriers to care, including ongoing illicit drug or alcohol use, 
ongoing uncontrolled neuropsychiatric disease, and poorly controlled HIV disease. 
[50] A major strength of this study was its ability to characterize these barriers to 
care. One weakness of the study was that it restricted the analysis of reasons for not 
initiating HCV therapy to only those patients who finished HCV clinical staging. 
However, a significant proportion of patients referred for HCV therapy, 53 of 303 
(17%), either never showed up for their HCV appointment or did not return after their 
first HCV appointment, and were excluded from their analysis. [50] Additionally, as 
with all single site studies, these results may not be generalizable across care settings 
with different patient populations. 
 Maier et al. (2014) aimed to estimate the impact of the availability of DAAs 
on the care continuum for HIV/HCV coinfected persons, with a focus on treatment 
eligibility. Maier’s analysis is the first to use a multi-year, statewide, population-
based sample to estimate HCV treatment eligibility in HIV/HCV coinfected patients, 
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and the first to estimate eligibility in the setting of an interferon-free regimen. [51] Of 
161 coinfected patients living in Oregon during 2007-2010, 21% were eligible for 
HCV therapy, and eligibility assuming an interferon-free regimen increased only to 
26%, mostly due to numerous simultaneous contraindications. [51] Active alcohol 
abuse was the most common contraindication (24%), followed by uncontrolled 
mental health (22%), recent injection drug use (21%), and poor antiretroviral 
adherence (22%). [51] Additional strengths of this study include use of both medical 
record abstraction and a structured interview as data sources, and use of data from the 
modern antiretroviral time period. Limitations of the study include assumption of 
chronic infection given anti-HCV positivity, as few patients had HCV viral load 
testing, and lack of generalizability of results to other geographical areas.  
 While the retrospective cohort studies described above are able to provide 
estimates of the care continuum at a given point in time, prospective studies are able 
to shed light on changes in the care continuum over time. Grint et al. (2013) 
conducted a prospective cohort study in association with EuroSIDA, a cohort of 
18,295 HIV-positive individuals in 105 centers across Europe, Israel and Argentina. 
[42] Grint et al. studied all patients in EuroSIDA with viremic HCV infection, and 
used Poisson regression was used to identify temporal changes 
and regional differences in HCV treatment uptake. [42] The study included a total of 
1984 coinfected patients, of whom 501 (25.3%) received HCV therapy. [42] 
Treatment incidence rose from 0.33 (95% CI 0.16-0.50) per 100 person-years of 
follow-up in 1998 to 5.93 (95% CI 4.49-7.38) in 2007, and fell to 3.78 (95% CI 2.50-
5.07) in 2009. [42] A CD4 cell count > 350 cells/µL and liver fibrosis ≥ F2 were 
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predictors of anti-HCV treatment initiation on adjusted analyses. [42] A strength of 
this study is its ability to record patients’ HCV status over time and to associate 
demographic and clinical characteristics with treatment initiation and completion. 
Limitations of this study include failure to characterize contraindications for initiating 





CHAPTER 3: STUDY METHODS 
 
3.1) Study Design  
 
We conducted a retrospective review of the medical records of patients 
reported as having HCV infection at the Nathan Smith HIV clinic of Yale-New 
Haven Hospital from June 2002 through January 2014 (n = 135), collecting data 
points for each patient including: demographics, clinical characteristics related to 
HCV and HIV, other medical comorbidities, linkage to care, prescription of HIV and 
HCV treatment, HCV treatment course, and outcomes. Clinical data collected for 
each subject were the current or most recent at the time of their most recent HCV 
treatment evaluation, unless no evaluation occurred, in which case data were 
collected from the most recent clinical encounter at the Nathan Smith Clinic. 
This study is unique amongst prior published studies of the HCV care 
continuum in two ways. First, it examines a large sample of HIV/HCV coinfected 
patients in the DAA era. Second, it classifies care outcomes as optimal or suboptimal, 




Figure 1: The HCV Cascade of Care, showing steps of the cascade, definitions of 
each step, and barriers to care at each step. Text in red indicates suboptimal 
outcomes, while text in green indicates optimal outcomes. HCV = hepatitis C virus, 
SVR = sustained virologic response, Ab = antibody,  AASLD = American 
Association for the Study of Liver Diseases. 
 
3.2) Study Population, Eligibility and Sampling 
 
The study population included all HCV-positive patients from the Nathan 
Smith Clinic of the Yale-New Haven Hospital, an urban HIV referral clinic in New 
Haven, CT associated with the Yale Medical Group and the Yale School of Medicine. 
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Eligibility criteria were defined as patients in care from June 2002 through January 
2014, and having a current diagnosis of HCV by ICD-9 code, verified by current anti-
HCV positivity and/or detectable HCV viral load in the clinical record. 
 
3.3) Study Variables and Measures 
 
Definitions of HIV/HCV coinfection 
• HCV diagnosis: The subject must have at least one positive anti-HCV 
antibody test and/or HCV RNA (the latter accepted for active cases) 
• Chronic HCV infection: The subject must have persistent HCV RNA, i.e. at 
least one HCV RNA result greater than undetectable > 6 months from time of 
first diagnosis 
• HIV infection: The subject must have at least one positive anti-HIV 1 or 2 
antibody result 
• AIDS Diagnosis by low CD4 count only: The subject must have at least one 
CD4 count under 200 cells / µl and no recorded history of opportunistic 
infection 
• AIDS Diagnosis by low CD4 count and OI: The subject must have at least one 
CD4 count under 200 cells / µl and a recorded history of at least one 
opportunistic infection, per CDC guidelines of AIDS-defining criteria [52] 
 
Definitions of medical comorbidities 
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• All medical comorbidities were identified by provider documentation from a 
primary care provider and/or an HCV treatment specialist, by ICD-9 code 
and/or explicit mention in a provider note 
 
Definitions of care continuum stages 
• Referral to care: The subject must have a provider note explicitly stating 
referral to an HCV treatment specialist, have a clinical appointment scheduled 
with an HCV treatment specialist, or attend an evaluation with an HCV 
treatment specialist 
• Treatment evaluation: The patient must have had at least one clinical 
encounter with an HCV treatment specialist for the purpose of HCV treatment 
evaluation 
• Treatment eligibility: The subject must be evaluated by an HCV treatment 
specialist and either explicitly deemed to be a candidate for treatment, be 
recommended to initiate treatment, or be prescribed treatment 
 
Definitions of suboptimal care outcomes 
• Patient declined: The subject must have declined to be referred for treatment 
evaluation or declined to be prescribed treatment, while the provider 
recommended referral or prescription of treatment, as explicitly stated in a 
provider note 
• Loss of linkage to care: The subject must have at least one clinical encounter 
to establish care with a primary care provider or HCV specialist, but fail to 
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present to future scheduled appointments without being in regular contact with 
the clinic 
• No referral, reason unknown: The subject must have no documentation in the 
clinical record of having been referred for HCV treatment AND have no 
documented reason for non-referral  
 
Definitions of optimal care outcomes 
• Infection cleared: The subject must have at least one positive anti-HCV 
antibody result and an undetectable HCV RNA at most recent laboratory 
evaluation in the absence of treatment 
• Not treatment candidate: The subject must have been deemed “not a candidate 
for treatment” as explicitly stated in a provider note from a primary care 
provider or HCV treatment specialist 
• Awaiting initial evaluation: The subject must have been referred for HCV 
initial treatment evaluation and have a future scheduled appointment for this 
evaluation 
• Undergoing evaluation: The subject must have had an initial evaluation with 
an HCV treatment specialist, but no decision had yet been made at the time of 
data collection regarding treatment eligibility 
• Deferred therapy: The subject must have had at least one HCV treatment 
evaluation, with a provider note from the encounter explicitly recommending 
deferred therapy 
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• Undergoing therapy: The subject must have initiated HCV treatment but not 
yet completed the prescribed treatment course 
 
Definitions of treatment outcomes:  
• Partial response: ≥ 2 log 10 reduction from baseline HCV RNA at week 12, but 
virus remains detectable through week 24 or end of treatment (applies to 
therapy with interferon based regimens and first generation DAAs boceprevir 
and telaprevir) 
• Null-response: <2 log 10 reduction from baseline HCV RNA during treatment 
(applies to therapy with interferon based regimens and first generation DAAs 
boceprevir and telaprevir) 
• End-of-treatment response (ETR): undetectable HCV RNA at the end of 
planned treatment course 
• Sustained virologic response (SVR): undetectable HCV RNA at 12-24 weeks 
after treatment completion 
• Relapse: undetectable viremia during treatment and/or at the end of treatment, 
but subsequent viremia typically occurring within 24 weeks following 
treatment cessation 
 
3.4) Data Collection 
 
All data collection was conducted by the author of this thesis. Clinical data 
were abstracted over the period -August 2014 to December 2014- from electronic 
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medical records of identified eligible patients into an electronic case report form 
and/or password protected MS Excel © database. Each patient was assigned a unique 
code prior to entry of data into the case report form and/or study database to minimize 
risk of patient identification. The master lists linking patient names/identifiers to the 
study database were stored in an encrypted password protected file, known only to the 
research team. Similarly, all electronic study data was stored in encrypted and 
password-protected laptop computers. Electronic data without PHI was stored on an 
encrypted USB drive that is password protected, available only to the principal 
investigator, sub-investigators, and research coordinators.  
 
3.5) Data Analysis / Statistics 
 
All data analysis was conducted by the author of this thesis. The number of 
patients progressing through each stage of the treatment cascade were expressed as 
proportions of the total study population (simple frequencies and/or percentages). 
Reasons for failure of progression (“drop-offs”) along the HCV treatment cascade 
were captured and reported as optimal or suboptimal outcomes, including the number 
of patients who met the pre-defined criteria for the outcomes. Binary logistic 
regression analyses were conducted to investigate factors associated with not being 
referred for HCV treatment evaluation and not being prescribed HCV treatment, 
while adjusting for other related variables, using SPSS version 22 (IBM, Armonk, 
New York). Bivariate analyses were conducted to obtain unadjusted data for factors 
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shown to be significant predictors in the regression analyses. A p value ≥ 0.05 was 
considered statistically significant. 
 
 
3.6) Timeline and Resources 
 
Study conception and design occurred from April 2014 to July 2014 with 
subsequent study approval obtained from the Yale University Institutional review 
Board (Human Investigations Committee - HIC). Data collection was then conducted 
over the period from August 2014 to December 2014. Data analysis was performed 
from December 2014 to February 2015. Drafting and multiple revisions of the thesis 
occurred over the period of January 2015 to February 2015. Funding for the study 
was provided by the Yale School of Medicine Office of Student Research, on a 
monthly basis, over the period of June 2014 to December 2014.  
 
3.7) Subject Protection and Confidentiality 
 
All portable devices and desktop computers contained encryption software by 
Yale University Information Technology Services (ITS). Data was maintained as 
accessible only to the investigator and study personnel listed on the Human 
Investigation Committee (HIC) application. The principal investigator was 
responsible for monitoring the data and assuring protocol compliance. Either the 
principal investigator or the HIC maintained the authority to stop or suspend the study 
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or require modifications. In compliance with the ICH/GCP guidelines, the 
investigators took measures to prevent accidental or premature destruction of these 
documents or loss of data.  When the project is complete, the password encrypted 
data and/or identifiers will be destroyed by electronically and securely deleting all 




CHAPTER 4: RESULTS 
 
4.1) Study Subject Demographics 
 
The majority of the study population was male (62.22%), and the male-to-
female ratio was 1.65 to 1 (see Table 1a). The median age of the population was 56 
years, and the interquartile range was 50.9 years to 59.4 years.  The majority of the 
study population was 55-64 years of age (51.85%), most subjects were between 45 
and 64 years of age (89.63%), and 4.44% were elderly (age ≥ 65). The population 
was racially diverse, with the highest proportion identifying as black (48.89%) 
followed by white (32.59%) and Hispanic/Latino (17.04%), and no patients identified 
as Asian. Only 8.15% of the study population was homeless, and none were 
incarcerated while in care. The vast majority of subjects had public insurance 
(91.85%), most were unmarried (82.96%), and the majority of the study population 
was unemployed (65.19%). While more than half resided in New Haven (56.30%), a 
large amount (43.70%) commuted to the clinic from surrounding areas. 
 
Table 1a: Demographic characteristics of study population 
N	  or	  median	   %	  or	  IQR	  
Gender	   Male	   84	   62.22%	  
	   Female	   51	   37.78%	  
Age	   Median	  Age	   	   56	   50.92	  -­‐	  59.42	  
	   <	  45	   8	   5.93%	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   45-­‐54	   51	   37.78%	  
	   55-­‐64	   70	   51.85%	  
	   ≥	  65	   6	   4.44%	  
Race	  /	  Ethnicity	   White	   44	   32.59%	  
	   Black	   66	   48.89%	  
	   Latino	   23	   17.04%	  
	   Asian	   0	   0.00%	  
	   Other	   2	   1.48%	  
Housing	  Status	   Personal	  Residence	   114	   84.44%	  
	   Extended	  Care	  Facility	   10	   7.41%	  
	   Homeless	   11	   8.15%	  
	   Prison	   0	   0.00%	  
Insurance	   Public	   124	   91.85%	  
	   Private	   9	   6.67%	  
	   Uninsured	   2	   1.48%	  
Marital	  Status	   Married	   23	   17.04%	  
	   Single/Other	   112	   82.96%	  
Employment	   Employed	   22	   16.30%	  
	   Unemployed	   88	   65.19%	  
	   Unknown	   25	   18.52%	  
Resident	  City	   New	  Haven	   76	   56.30%	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   Other	   59	   43.70%	  
 
The majority of study subjects had no significant medical comorbidity 
(52.59%) (see Table 1b). The most common medical comorbidity among the study 
subjects was diabetes mellitus (16.30%), followed by portal hypertension (14.81%) 
and anemia (11.11%). No patients were pregnant at their most recent treatment 
evaluation or most recent clinical encounter. More than half of patients had at least 
one psychiatric comorbidity or substance abuse disorder (60.00%), with the most 
common comorbidities being depression (40.00%), active drug abuse (22.22%) and 
active alcohol abuse (16.30%). 
 
Table 1b: Comorbidities of study population 
N	   %	  
Medical	  Comorbidities	   	   	  
	   Hepatic	  Decompensation	   9	   6.67%	  
	   Portal	  Hypertension	   20	   14.81%	  
	   Diabetes	  Mellitus	   22	   16.30%	  
	   Renal	  Disease	   12	   8.89%	  
	   Chronic	  Obstructive	  Pulmonary	  Disease	   12	   8.89%	  
	   Heart	  Failure	   2	   1.48%	  
3.70%	  	   Thyroid	  Disease	   5	  
	   Anemia	   15	   11.11%	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   Leukopenia	   4	   2.96%	  
	   Thrombocytopenia	   10	   7.41%	  
	   Hemophilia	   2	   1.48%	  
	   Autoimmune	  Disease	   2	   1.48%	  
	   Malignancy	   9	   6.67%	  
	   Pregnancy	   0	   0.00%	  
	   None	   71	   52.59%	  
Psychiatric	  /	  Social	  Comorbidities	   	   	  
	   Depression	  (or	  other	  mood	  disorder)	   54	   40.00%	  
	   Schizophrenia	   5	   3.70%	  
	   Active	  alcohol	  abuse	   22	   16.30%	  
	   Active	  drug	  abuse	   30	   22.22%	  
	   None	   54	   40.00%	  
 
 
Of the patients with known HCV viral load (88.63% of study population), the 
median HCV viral load was 2,430,000 copies/µl (IQR: 521,000 - 6,448,647), 72.73% 
had HCV viral load greater than 600,000 copies/µl, and 28.93% had HCV viral load 
greater than 6,000,000 copies/µl (see Table 1c). The majority of patients had 
genotype 1 infection (71.11%), with nearly half of the study population having 
subtype 1a infection (47.41%). There were small numbers of patients with genotypes 
2 (3.70%), 3 (6.67%), and 4 (2.22%) infection. For the majority of patients, the IL-
28B genotype was unknown (65.19%). Injection drug use (IDU) was the most 
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commonly reported risk factor for HCV acquisition (69.63%). Most patients 
(84.44%) had never previously received HCV treatment.  
 
Table 1c: HCV-related clinical characteristics of study population 
N	  or	  median	   %	  or	  IQR	  
HCV	  Viral	  Loads	   Median	  VL	   2,430,000	   521,000	  –	  
6,448,647	  
(copies/µl	  of	  blood)	   >	  600,000	   	   88	   72.73%	  	  
	   >	  6,000,000	   	   35	   28.93%	  
	   Unknown	   	   14	   10.37%	  
HCV	  Genotype	   1a	   	   64	   47.41%	  
	   1b	   	   15	   11.11%	  
	   1	  (subtype	  unknown)	   17	   12.59%	  
	   1	  (total)	   	   96	   71.11%	  
	   2	   	   5	   3.70%	  
	   3	   	   9	   6.67%	  
	   4	   	   3	   2.22%	  
	   Unknown	   	   22	   16.30%	  
IL-­‐28B	  Genotype	   CC	   	   9	   6.67%	  
	   CT	   	   25	   18.52%	  
	   TT	   	   13	   9.63%	  
	   Unknown	   	   88	   65.19%	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Mode	  of	  HCV	  Acquisition	  (Risk	  Factors)	   	   	  
	   Injection	  Drug	  Use	   	   94	   69.63%	  
	   Sexual	   	   6	   4.44%	  
	   Blood	  Products	   7	   5.19%	  
	   Intranasal	  Cocaine	   4	   2.96%	  
	   Tattoo	  /	  Scarification	   2	   1.48%	  
	   Health	  Care	  Associated	   0	   0.00%	  
	   Unknown	   30	   22.22%	  
Treatment	  Naïve	   Yes	   114	   84.44%	  
	   No	   21	   15.56%	  
 
 
The most commonly reported risk factors for HIV transmission were injection 
drug use (69.63%) and heterosexual contact (37.04%) (see Table 1d). The median 
CD4 count of the study population was 521 cells/µl (IQR: 304 – 787.5). The majority 
of patients had serum HIV viral loads less than 20 copies/ml (65.93%), and 42.96% 
had undetectable serum HIV viral loads. The majority of patients had never been 
diagnosed with AIDS (52.59%), and only 23.70% had a history of opportunistic 
infection. The majority of subjects (91.85%) were on antiretroviral therapy (ART), 
and 8.15% were not taking any ART. Broken down by classes, the antiretroviral 
therapy for 22.22% included a non-nucleoside reverse-transcriptase inhibitor 
(NNRTI), 51.85% included a protease inhibitor (PI), and 35.56% included an 
integrase strand transfer inhibitor (INSTI). 
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Table 1d: HIV-related risk factors and clinical characteristics of study population 
N	  or	  median	   %	  or	  IQR	  
Mode	  of	  HIV	  Acquisition	  (Risk	  Factors)	   	   	   	  
	   Injection	  Drug	  Use	   	   94	   69.63%	  
	   Homosexual	   	   7	   5.19%	  
	   Heterosexual	   	   50	   37.04%	  
	   Blood	  Products	   	   4	   2.96%	  
	   Vertical	   	   0	   0.00%	  
	   Health	  Care	  Associated	   0	   0.00%	  
	   Unknown	   	   13	   9.63%	  
CD4	  Count	   Median	  CD4	  Count	   	   521	   304	  –	  787.5	  
HIV	  Viral	  Load	   <	  20	  (includes	  undetectable)	   89	   65.93%	  
(copies/ml)	   Undetectable	   	   58	   42.96%	  
AIDS	  Diagnosis	   Low	  CD4	  count	   	   32	   23.70%	  
	   OI	  only	   	   0	   0.00%	  
	   Both	  (low	  CD4	  and	  OI)	   	   32	   23.70%	  
	   None	   	   71	   52.59%	  
ART	  	   On	  ART	   	   124	   91.85%	  
	   Not	  on	  ART	   	   11	   8.15%	  
NRTI	  Total	   	   117	   86.67%	  
	   3TC	  only	   	   2	   1.48%	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   TDF	  only	   	   1	   0.74%	  
	   ABC	  /	  3TC	   	   20	   14.81%	  
	   ABC	  /	  TDF	   	   1	   0.74%	  
	   AZT	  /	  3TC	   	   2	   1.48%	  
	   TDF	  /	  FTC	   	   91	   67.41%	  
	   NNRTI	  Total	   	   30	   22.22%	  
	   EFV	   	   17	   12.59%	  
	   ETR	   	   2	   1.48%	  
	   NVP	   	   2	   1.48%	  
	   RPV	   	   9	   6.67%	  
	   PI	  Total	   	   70	   51.85%	  
	   ATV	   	   6	   4.44%	  
	   ATV	  /	  RTV	   	   35	   25.93%	  
	   DRV	  /	  RTV	   	   23	   17.04%	  
	   LPV	  /	  RTV	   	   5	   3.70%	  
	   NFV	   	   1	   0.74%	  
	   INSTI	  Total	   	   48	   35.56%	  
	   RAL	   	   30	   22.22%	  
	   DTG	   	   8	   5.93%	  
	   EVG	  +	  cobicistat	   	   10	   7.41%	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Key to Acronyms: 3TC = lamivudine; ABC = abacavir; ATV = atazanavir; AZT = 
zidovudine; DRV = darunavir; DTG = dolutegravir; EFV = efavirenz; ETR = 
etravirine; EVG = elvitegravir; FTC = emtricitabine; INSTI = integrase strand 
transfer inhibitor; LPV = lopinavir; NFV = nelfinavir; NNRTI = non-nucleoside 
reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; 
NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; 
RTV = ritonavir; TDF = tenofovir disoproxil fumarate 
 
About one quarter (24.44%) of the study population had known cirrhosis (see 
Table 1e). Of patients with cirrhosis, 27.27% had decompensated disease. The most 
commonly experienced complications of cirrhosis were ascites (36.36%) and 
esophageal varices (36.36%). The proportion of patients having liver fibrosis 
evaluation was 41.48% for liver biopsy and 27.41% for Fibrospect II. Metavir and 
Fibrospect II scores were unknown for the majority of patients (58.52% and 72.59% 
respectively). Of patients with known Metavir scores, 76.79% had F2 or greater 
fibrosis, and of patients with known Fibrospect II scores, 72.97% had F2 or greater 
fibrosis. 
 
Table 1e: Liver disease severity of study population 
	   	   	   N	   %	  
Cirrhosis	   Yes	   33	   24.44%	  
	   No	   37	   27.41%	  
	   Unknown	   65	   48.15%	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Cirrhosis	  Classification	   Compensated	   24	   72.73%	  
	   Decompensated	   9	   27.27%	  
	   Total	   33	   	  
Cirrhosis	  Complications	   PSE	   9	   27.27%	  
	   SBP	   0	   0.00%	  
	   Ascites	   12	   36.36%	  
	   Varices	   12	   36.36%	  
Metavir	  Score	   Known	   56	   41.48%	  
	   0	   3	   5.36%	  
	   1	   10	   17.86%	  
	   2	   19	   33.93%	  
	   3	   9	   16.07%	  
	   4	   15	   26.79%	  
	   Unknown	   79	   58.52%	  
Fibrospect	  II	  Score	   Known	   37	   27.41%	  
	   F0-­‐F1	   10	   27.03%	  
	   F2-­‐F4	   27	   72.97%	  
	   Unknown	   98	   72.59%	  
 
   
4.2) The Care Continuum 
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Of 135 total patients diagnosed with chronic HCV, only 96 were referred for 
HCV treatment evaluation, a drop-off of 29% (see Figure 2). Of the 96 referred, 91 
had a treatment evaluation, a decrease of 5%. Of the 91 evaluated, 49 were deemed 
eligible for HCV treatment, a decline of 46%. Of the 49 eligible for treatment, only 
28 were prescribed HCV treatment, a drop-off of 43%. Finally, 17 subjects achieved 
SVR, with a decrease of 39%. 
 
 
Figure 2: The HCV Care Continuum among HIV/HCV Coinfected Patients at the 
Nathan Smith Clinic, 2002-2014. The horizontal axis represents the sequential steps 
of the continuum. The vertical axis denotes the number of patients progressing 
through each step of the continuum, labeled in black numbers above each column. 
The red arrows and percentages designate the proportion of patients from the previous 
step who drop off before achieving the next step. HCV = hepatitis C virus, SVR = 
sustained virologic response. 
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4.3) Factors Impacting Optimal Management Outcomes 
 
Of 135 total patients in the study population, 71% were referred for treatment, 
67% had a treatment evaluation, 36% were eligible for treatment, 21% were 
prescribed treatment, and 13% achieved SVR (see Figure 3). More than half (54%) of 
patients not referred for treatment were deemed not to be candidates for treatment, 
and 13% of patients not referred for treatment had cleared their HCV infection. Some 
of these patients (10%) declined to consider treatment, and others (18%) had no 
discernable reason for lack of referral. Of the 42 patients who have been evaluated for 
HCV treatment but not deemed eligible for treatment, 64% were deemed not a 
treatment candidate while 31% were still undergoing evaluation. Of the 21 patients 
deemed eligible for HCV treatment but not prescribed treatment, 71% were 
recommended to defer therapy, 24% declined to undergo treatment, and 5% could not 
receive treatment due to a problem with insurance coverage. Of the 11 patients 
prescribed HCV treatment that did not achieve SVR, 55% were still undergoing 




Figure 3: Optimal and Suboptimal Outcomes in the HCV Care Continuum. 
Percentages for each outcome describe the proportion of the patients who drop off the 
continuum at the designated location due to the designated outcome. Patients 
experiencing treatment failure return to the beginning of the care continuum. 
  
 Of the 107 patients who were not prescribed HCV treatment, the most 
common reason for not initiating treatment was not being deemed a treatment 
candidate (45.79%) (see Table 2a). 
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Table 2a: Reasons for not initiating treatment 
	   N	   %	  
Infection	  cleared	   5	   4.67%	  
Awaiting	  initial	  evaluation	   3	   2.80%	  
Undergoing	  evaluation	   13	   12.15%	  
Deferred	  therapy	   15	   14.02%	  
Patient	  declined	   9	   8.41%	  
Not	  candidate	   49	   45.79%	  
Loss	  of	  linkage	  to	  care	   5	   4.67%	  
No	  referral	  for	  treatment	  evaluation	  (reason	  unknown)	   7	   6.54%	  
Lack	  of	  insurance	  coverage	   1	   0.93%	  
Total	   107	   	  
 
 Of patients deemed not to be treatment candidates, the most common reasons 
given were non-adherence to ART / poorly controlled HIV (51.02%), active drug 
abuse (40.82%), and active alcohol abuse (26.53%) (see Table 2b). 
 
Table 2b: Reasons for non-candidacy for HCV treatment 
N	   %	  
Active	  alcohol	  abuse	   13	   26.53%	  
Active	  drug	  abuse	   20	   40.82%	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ART	  non-­‐adherence	  /	  poorly	  controlled	  HIV	   25	   51.02%	  
Decompensated	  cirrhosis	   5	   10.20%	  
Uncontrolled	  depression	   4	   8.16%	  
Uncontrolled	  Diabetes	  Mellitus	   3	   6.12%	  
Malignancy	   3	   6.12%	  
End	  Stage	  Renal	  Disease	   2	   4.08%	  
Thrombocytopenia	   1	   2.04%	  
 
  
4.4) Predictors of Suboptimal Outcomes across the Care Continuum 
 
Using a binary logistic regression model, significant predictors of not being 
referred for HCV treatment evaluation include female gender (odds ratio: 0.240, 95% 
confidence interval: 0.064 - 0.907, p = 0.035), depression (OR: 0.215, 95% CI: 0.057 
- .812, p = 0.023), and high HIV viral load (for each 1 log increase in viral load, OR: 
0.608, 95% CI: 0.373 - 0.992, p = 0.046) (see Table 3a). Having a higher number of 
medical comorbidities was positively associated with HCV treatment referral (for 
each additional comorbidity, OR: 2.054, 95% CI: 1.084 - 3.892, p = 0.027). These 
predictors were significant after controlling for the other variables in the model. Age, 
race, transmission risk factors, alcohol and drug abuse, HCV genotype, HCV viral 




Table 3a: Predictors of treatment referral using a binary logistic regression model 
Odds	  Ratio	  
(OR)	  
95%	  C.I.	  	  
Lower	  
95%	  C.I.	  
Upper	   p-­‐value	  
	  
	  
Demographic	  Information	   	   	   	   	  
Age	   0.968	   0.870	   1.078	   0.555	  
Female	  gender	   0.240	   0.064	   0.907	   0.035	  
Black	  	   0.843	   0.208	   3.405	   0.810	  
Latino	   1.785	   0.248	   12.818	   0.565	  
Homeless	   2.669	   0.169	   42.217	   0.486	  
Married	   1.064	   0.150	   7.539	   0.951	  
Lives	  outside	  New	  Haven	   0.979	   0.275	   3.483	   0.974	  
Injection	  Drug	  Use	   0.716	   0.147	   3.491	   0.680	  
Blood	  Products	   0.639	   0.033	   12.207	   0.766	  
Homosexual	   0.487	   0.034	   6.987	   0.596	  
	   	   	   	   	  
Comorbidities	   	   	   	   	  
Depression	   0.215	   0.057	   0.812	   0.023	  
#	  of	  Medical	  Comorbidities	   2.054	   1.084	   3.892	   0.027	  
Active	  Alcohol	  Abuse	   3.306	   0.427	   25.625	   0.252	  
Active	  Drug	  Abuse	   0.361	   0.081	   1.618	   0.183	  
	   	   	   	   	  
HCV	  Information	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Genotype	  2	   3.836	   0.205	   71.686	   0.368	  
Genotype	  4	   0.881	   0.050	   15.530	   0.931	  
Genotype	  unknown	   0.032	   0.001	   1.182	   0.062	  
log10(HCV	  Viral	  Load)	   0.842	   0.501	   1.415	   0.516	  
	   	   	   	   	  
HIV	  Information	   	   	   	   	  
CD4	  Count	   1.002	   1.000	   1.005	   0.088	  
AIDS:	  CD4	  only	   1.346	   0.210	   8.646	   0.754	  
AIDS:	  CD4	  +	  OI	   1.269	   0.244	   6.590	   0.777	  
log10(HIV	  Viral	  Load)	   0.608	   0.373	   0.992	   0.046	  
                                        Cox	  &	  Snell	  R	  square:	  0.332,	  Nagelkerke	  R	  square:	  0.492	  
  
Using bivariate analysis, female gender (OR: 0.334, 95% CI: 0.155 - 0.721, p 
= 0.005), depression (OR: 0.284, 95% CI: 0.131 - 0.617, p = 0.001), and high HIV 
viral load (OR: 0.695, 95% CI: 0.544 - 0.889, p = 0.004) remained significant 
predictors of not being referred for HCV treatment evaluation (see Table 3b). The 
number of medical comorbidities was not a significant predictor of treatment referral 
using this analysis, which does not control for any other variables in the study. 
 
Table 3b: Predictors of HCV treatment referral using bivariate analysis 
Odds	  Ratio	  
(OR)	  
95%	  C.I.	  	  
Lower	  
95%	  C.I.	  
Upper	   p-­‐value	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Female	  gender	   0.334	   0.155	   0.721	   0.005	  
Depression	   0.284	   0.131	   0.617	   0.001	  
#	  of	  Medical	  Comorbidities	   1.321	   0.938	   1.861	   0.111	  
log10(HIV	  Viral	  Load)	   0.695	   0.544	   0.889	   0.004	  
  
Using a binary logistic regression model, significant predictors of not being 
prescribed HCV treatment include black race (compared to white, OR: 0.018, 95% 
CI: 0.001 - 0.307, p = 0.006), high HIV viral load (OR: 0.106, 95% CI: 0.025 - 0.458, 
p = 0.003), and having AIDS diagnosis by both CD4 count and history of 
opportunistic infection (OI) (OR: 0.037, 95% CI: 0.001 - 0.924, p = 0.045) (see Table 
3c). These predictors were significant after controlling for the other variables in the 
model. Age, gender, date of treatment evaluation, number of number medical 
comorbidities, depression, alcohol and drug abuse, cirrhosis, HCV genotype, HCV 
viral load, and ART regimen were not predictive of being prescribed HCV treatment 
in this model. 
 




95%	  C.I.	  	  
Lower	  
95%	  C.I.	  
Upper	   p-­‐value	  
	  
	  
Demographic	  Information	   	   	   	   	  
Age	   1.260	   0.990	   1.602	   0.060	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Female	  gender	   0.370	   0.049	   2.810	   0.337	  
Black	  	   0.018	   0.001	   0.307	   0.006	  
Latino	   0.447	   0.025	   8.026	   0.585	  
Evaluated	  after	  12/6/2013	   0.558	   0.095	   3.269	   0.518	  
	   	   	   	   	  
Comorbidities	   	   	   	   	  
Depression	   0.518	   0.074	   3.643	   0.509	  
#	  of	  Medical	  Comorbidities	   0.773	   0.362	   1.653	   0.507	  
Active	  Alcohol	  Abuse	   1.345	   0.075	   24.250	   0.841	  
Active	  Drug	  Abuse	   0.130	   0.008	   2.037	   0.146	  
Cirrhosis	   2.243	   0.166	   30.315	   0.543	  
	   	   	   	   	  
HCV	  Information	   	   	   	   	  
Genotype	  2	   3.227	   0.022	   469.629	   0.645	  
Genotype	  3	   0.071	   0.003	   1.526	   0.091	  
Genotype	  4	   0.345	   0.000	   10067	   0.839	  
Genotype	  unknown	   0.026	   0.000	   115.781	   0.394	  
log10(HCV	  Viral	  Load)	   0.625	   0.194	   2.019	   0.433	  
	   	   	   	   	  
HIV	  Information	   	   	   	   	  
AIDS:	  CD4	  only	   1.311	   0.149	   11.556	   0.807	  
AIDS:	  CD4	  +	  OI	   0.037	   0.001	   0.924	   0.045	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log10(HIV	  Viral	  Load)	   0.106	   0.025	   0.458	   0.003	  
	   ART:	  TDF	  /	  FTC	   0.070	   0.000	   43.479	   0.418	  
	   ART:	  ABC	  /	  3TC	   0.008	   0.000	   5.286	   0.146	  
	  	  	  	   	   	   	  	  	  	  	  	  	  	  	  	  Cox	  &	  Snell	  R	  square:	  0.464,	  Nagelkerke	  R	  square:	  0.662 
  
 Using bivariate analysis, high HIV viral load (OR: 0.518, 95% CI: 0.320 - 
0.840, p = 0.008) and having AIDS diagnosis by both CD4 count and history of OI 
(OR: 0.182, 95% CI: 0.040 - 0.838, p = 0.029) remained significant predictors of not 
being prescribed treatment for HCV (see Table 3d). Black race compared to white 
was not a significant predictor of being prescribed HCV treatment in this analysis, 
which does not control for any other variables in the study. 
 




95%	  C.I.	  	  
Lower	  
95%	  C.I.	  
Upper	   p-­‐value	  
Black	   0.447	   0.171	   1.172	   0.102	  
log10(HIV	  Viral	  Load)	   0.518	   0.320	   0.840	   0.008	  
AIDS:	  CD4	  +	  OI	   0.182	   0.040	   0.838	   0.029	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CHAPTER 5: DISCUSSION 
 
5.1) Key Findings 
 
Our results show that in a real-world setting, an urban outpatient HIV clinic, 
few HIV-infected individuals diagnosed with chronic HCV infection achieve 
virologic cure of HCV, and that there are multiple barriers that lead to significant 
drop-offs between stages along the HCV care continuum.  
In our analysis, only 13% of the study population achieved SVR. While low, 
this is higher than the proportion reported by Kramer et al. (3.5%) and Yehia et al. 
(9%). [47, 48] However, these results may not be directly comparable due to 
differences in study population. Kramer et al. studied HCV monoinfected patients in 
the VA healthcare system. Yehia et al. also studied monoinfected patients, and used 
an estimate of all patients with chronic HCV infection, not a group of individuals 
with diagnosed HCV infection, as the denominator for their proportion. When 
readjusted as a percentage of only those with diagnosed chronic HCV infection, the 
proportion achieving SVR in their analysis was 18%.  
Cachay et al., a study of a similar patient population (HIV/HCV coinfected 
patients in care at an HIV-referral clinic), reported that only 7% of patients diagnosed 
with chronic HCV achieved SVR. [50] Since Cachay et al. captured data from as 
recently as 2012, the improved cure rates in our study may reflect the positive impact 
of introduction of DAAs in the recent two years. 
 
 66 
In our analysis, 36% of the study population had a treatment evaluation and 
were found to be eligible for HCV treatment, similar to the eligible proportion found 
by Kramer et al. (35.9%), but higher than that reported by other studies of HIV/HCV 
coinfected subjects, including Butt et al. (28.4%) and Maier et al. (21%). [47, 49, 51]  
Our results may reflect an improvement in treatment eligibility in the era of 
DAAs which became available and were used in the last two years of the study 
period. Compared to regimens containing interferon and ribavirin, treatment 
eligibility is vastly improved for the currently recommended DAA-based regimens as 
there are less clinical and laboratory contraindications to use of the drugs. While the 
analysis of Butt et al. used data from 2003, and that of Maier et al. used data from 
2010, our study captured clinical interactions as recently as December 2014. [49, 51] 
In fact, more than 67% of the treatment evaluations recorded in our study occurred 
after December 6, 2013, the date of FDA-approval of sofosbuvir (table 4). 
 
Table 4: Treatment Evaluation in the era of DAAs 
Treatment	  Evaluation	  after	  12/6/13	   N	   %	  
Yes	   61	   67.03%	  
No	   30	   32.97%	  
 
  
One of the strengths of our study was the ability to describe factors impacting 
drop-off between stages in the HCV care continuum. We identified three major drop-
offs points in the cascade: between HCV diagnosis and HCV treatment 
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referral/evaluation, treatment evaluation and treatment eligibility, and lastly, 
treatment eligibility and prescription of antiviral treatment. 
Of the 135 HIV-infected individuals diagnosed with HCV, while 71% were 
referred for HCV treatment evaluation, 67% had a formal evaluation by a HCV 
specialist. These proportions compare favorably to other analyses. Kramer et al. 
found that 60% of those diagnosed with HCV were evaluated for treatment. [47] 
Cachay et al. reported a 50% evaluation rate for patients with HIV/HCV coinfection. 
[50] Yehia et al. found that only 54% of those diagnosed with chronic HCV even had 
HCV RNA confirmation, and that only 34% had liver fibrosis evaluation. [48] 
Of the factors influencing drop-off between diagnosis and referral, the most 
common was not being deemed a treatment candidate (54%). Notably, the 
determination of treatment candidacy was typically determined by a patient’s primary 
care provider. The most common reasons for non-candidacy were non-adherence to 
ART / poorly controlled HIV (51.02%), active drug abuse (40.82%), and active 
alcohol abuse (26.53%). These factors are comparable to those identified by Maier et 
al., who found that the most common contraindications to therapy were active alcohol 
abuse (24%), uncontrolled mental health (22%), recent injection drug use (21%), and 
poor antiretroviral adherence (22%).  
While the above factors are relative contraindications to receiving HCV 
therapy, they become absolute when they preclude referral for treatment evaluation, 
eliminating any chance that treatment will be prescribed. This, however, may not be 
an optimal outcome, as history of non-adherence to ART may not be entirely 
predictive of non-adherence to HCV treatment, especially with new and better 
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tolerated DAA regimens that are prescribed for relatively short treatment durations. 
Furthermore, while ART non-adherence and substance abuse are difficult to treat, 
they are amenable to intervention, and if adequately addressed may indirectly 
increase HCV treatment referral. 
Of the suboptimal outcomes influencing drop-off between HCV diagnosis and 
treatment evaluation referral, the most common were patients not referred for 
evaluation by providers for unknown reasons (18%) and patients declining referral 
(10%). The former is provider-driven barrier, while the latter is patient-driven. There 
are numerous reasons why a provider may fail to refer a patient with chronic HCV for 
treatment evaluation: the provider may not be aware of the diagnosis, may not be 
aware of indications for treatment referral, or may not be aware of available and 
effective HCV treatment options or willing to prescribe them. These factors may be 
mitigated by increasing providers’ familiarity with HCV disease and its management, 
and development and implementation of HCV referral and treatment protocols. 
Patients declining to meet with an HCV treatment specialist need further education 
regarding the consequences of untreated chronic HCV infection in the context of HIV 
co-infection and the availability of safe and well-tolerated treatment regimens of short 
durations. 
The second major drop-off in our HCV care continuum was between 
treatment evaluation and treatment eligibility. Only 36% of the study population was 
deemed eligible for treatment, a decline of 46% from the group of patients who had a 
treatment evaluation. Kramer et al. reported a similar decline (40%) between 
evaluation and eligibility. Again, the primary reason for this drop-off was not being 
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deemed a treatment candidate. As discussed above, interventions targeting the 
primary reasons for non-candidacy (non-adherence and substance abuse) may 
indirectly improve HCV treatment eligibility. Promisingly, 31% of the decline at this 
point was due to patients still undergoing treatment evaluation who may yet progress 
further through the cascade. As progression through this stage is dependent on 
provider subjectivity, strict algorithms for evaluation and prescription of treatment 
may help eliminate this barrier to care. However, not all reasons for treatment non 
candidacy can be easily modified, including comorbid conditions such as abnormal 
renal function, severe cytopenias, and decompensated liver disease. 
The final major drop-off was between treatment eligibility and prescription of 
treatment. Our results show a decline of 43% at this step, which was significant but 
not as drastic as that reported by Kramer et al. (67.7%). [47] The major reason for 
failure to progress through this step was deferred therapy (71%), meaning that the 
patient was eligible for treatment but that the provider recommended deferral of 
prescription of treatment in the best interest of the patient. Deferring therapy may be a 
provider’s choice if they have knowledge of impending availability of new regimens 
that are safer, more effective, and/or better tolerated than those currently available, or 
if the patient needs to complete evaluation or treatment for another serious medical 
comorbidity, such as malignancy. In the era of interferon therapy, lack of severe liver 
disease was sometimes a reason to defer therapy, as the risk of harms resultant from 
highly toxic treatment was greater than the benefit of potential HCV cure for those 
with low risk of progression to cirrhosis. However, with newer well-tolerated and 
more effective regimens available, all patients with chronic HCV infection should be 
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considered for treatment. The concern for deferring HCV therapy is the possibility of 
progression of liver disease or risk of developing extra-hepatic complications of HCV 
infection. 
Other factors which may contribute to non-prescription of HCV treatment for 
potentially eligible individuals include drug-drug interactions between HCV and 
ARV drugs, particularly those of the protease inhibitor class (51.9% of our study 
population on ART). Furthermore, no or insufficient insurance coverage may also 
limit use of newer DAAs as it is factored into clinician decisions on whom to initiate 
therapy. 
The primary suboptimal outcome influencing drop-off between eligibility and 
treatment was patients declining to receive treatment (24%). The reasons for this 
observation is unclear. This is probably related to patients’ perception that they are at 
low risk of complications from HCV infection, or that treatments would result in 
significant side effects. Again, educating patients and providers about the availability, 
safety, efficacy and short duration of new treatment regimens will help to mitigate 
drop-off at this point in the continuum. 
By conducting logistic regression and bivariate analysis, we were able to 
identify demographic and clinical factors predictive of not being referred for 
treatment and not being prescribed treatment. Female gender, depression, and high 
HIV viral load were predictive of not being referred for treatment, while high HIV 
viral load and having AIDS diagnosis by both low CD4 count and history of 
opportunistic infection (OI) were predictive of not being prescribed treatment. 
Cachay et al. reported similar factors to be predictive of failing to achieve optimal 
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outcomes. Their analysis found that lack of engagement in care, unstable housing, 
having AIDS diagnosis, having detectable HIV viral load and being non-white were 
predictive of non-referral, while ongoing illicit drug or alcohol use, ongoing 
uncontrolled neuropsychiatric disease, and poorly controlled HIV disease were 
predictive of not receiving HCV treatment. [50] 
Our study found that female patients were much less likely to be referred for 
HCV treatment. There is evidence that women clear HCV infection more commonly 
than men, and experience slower rates of liver disease progression when chronically 
infected with HCV. [53, 54] Women also face unique barriers to treatment, including 
active pregnancy or the requirement for contraception for those with pregnancy 
potential to limit the risk of teratogenic effects from HCV drugs such as ribavirin. 
[55] The factors certainly impact HCV treatment evaluations and treatment eligibility. 
Lower rates of HCV treatment referral for female patients may reflect bias among 
primary care providers, as females who were evaluated for treatment were not less 
likely to be prescribed treatment by HCV treatment specialists. It may also indicate 
the presence of a confounding variable that was not included in the logistic regression 
analysis. 
Depression was found to be predictive of non-referral, but in practice should 
not prevent referral for HCV treatment. This was probably driven by treatment 
evaluations performed when interferon based regimens were the only treatment 
options, as even a history of depression or mood disorder was a serious 
contraindication to interferon therapy. However, newer DAAs are not associated with 
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causing or exacerbating mood disorders, but primary care providers may retain the 
notion that depression precludes HCV treatment. 
It was not surprising that our study found that having a high HIV viral load is 
predictive of both not being referred for evaluation and not receiving HCV treatment. 
It is plausible that patients who are prescribed ART and found with high viral loads 
are likely not engaged in regular care and/or not adherent to ART. For these patients, 
control of their HIV disease is often prioritized by providers over treatment of HCV 
infection. Furthermore, patients non-adherent with ART may also be non-adherent 
with HCV therapy. Having AIDS diagnosis by both low CD4 count and history of OI 
was also predictive of not being prescribed treatment, and this also likely reflects a 
group of patients with poor engagement in care and possibly poor adherence to ART. 
 
5.2) Real world obstacles to optimal HCV management 
  
 There are numerous real world obstacles to HCV management, some of which 
were not captured in our analysis. The population in our study included only patients 
with diagnosed chronic HCV infection, but poor testing rates can lead to large 
numbers of undiagnosed individuals. To address poor testing rates, New York State 
passed legislation that requires the offering of a HCV screening test to every 
individual born between 1945 and 1965 in both inpatient and outpatient care settings. 
[56] While similar legislation in other states or at the federal level will likely help to 
reduce the number of people with undiagnosed chronic HCV infection, as of yet no 
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study has tested whether this will lead to net clinical benefit or harm in screened 
populations. [57] 
 There are also multiple factors leading to lower eligibility rates for HCV 
treatment among HIV-infected patients compared to non HIV-infected clinical trial 
populations. As seen in our results, HIV-coinfected populations have higher rates of 
mental health disorders and substance abuse disorders than the general population. In 
addition, drug-drug interactions remain a major challenge for prescribers of HCV 
treatment. Patients may decline HCV therapy if they are unwilling to switch their 
ART regimen to one compatible with the planned HCV treatment regimen. Issues of 
drug-drug interaction are extremely common. Among our study population, 51.9% of 
subjects were on ART containing a protease inhibitor (PI), many of which have 
significant interaction with the currently recommended DAA-based regimens. 
Potentially, care algorithms could be designed to transition HIV-infected patients 
with known chronic HCV infection to compatible ART in anticipation of future HCV 
treatment. 
The prohibitive cost of newer treatments is another major obstacle to HCV 
management. The new DAA regimens can cost as much as $150,000 per treatment 
course, and recently, there has been a decision by many state Medicaid programs, to 
limit treatment only to individuals with advanced (F3 or F4) liver fibrosis. [58] 
Medicaid and Medicare insure a large proportion of HIV/HCV coinfected patients 
and such drug coverage decisions may weigh heavily on the patient population. As an 
example, 92% of our study population had public insurance. While those without 
advanced liver disease may not immediately suffer harm from untreated infection, 
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there remains a risk of transmission of HCV. Furthermore, while limiting access to 
treatment may yield short-term cost savings, it may lead to more patients requiring 
expensive liver transplants in the future. 
 
5.3) Study Limitations 
 
 One limitation of the HCV continuum of care model is the large amount of 
overlap of the stages of engagement in care. While we attempted to address this by 
creating strict definitions for each stage of the cascade, the imposed definitions used 
in allocating patients may limit inter-study comparisons. Also, as study data was 
collected retrospectively from pre-existing medical records, accuracy of study results 
is dependent on quality of documentation. As with any single-center study, it is 
unclear whether patients have been evaluated or treated at other centers.  
The spectrum of engagement in care as characterized in this high-risk, HIV-
coinfected patient population may not be generalizable to the total patient population 
with chronic HCV or to populations outside of the United States and in resource 
limited settings due to different patient and provider characteristics. Furthermore, the 
care continuum at the Nathan Smith Clinic may not be reflective of a typical 
community clinic, as it has a pool of providers who are familiar with and actively 
engaged in HCV management, and is affiliated with an academic center with access 
to clinic trials. 
 Although a strength of our analysis was the ability to designate care outcomes 
as optimal and suboptimal, there remain limitations to this approach. Patients 
undergoing treatment evaluation and undergoing therapy were classified as having 
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optimal outcomes at the time of data collection, but it is possible that these patients 
may not progress forward through the cascade and will not be captured by our 
analysis. Controversially, one may argue it is an optimal outcome not to treat an 
HCV-infected patient with a low risk of progression to cirrhosis, and therefore not at 
risk for developing HCC. However, this was a stronger argument when HCV 
treatment was more toxic and less effective, therefore, the risk-benefit calculus was 
more weighted toward risk. In the era of DAAs, the pendulum is swinging in the 
other direction with less risk of harms with treatment and high success rates. Lastly, 
we considered it an optimal outcome when a patient is deemed not a treatment 
candidate because it represents optimal management of the patient at the time of 
evaluation, but leaving chronic HCV infection untreated is certainly not optimal for 
the health of the patient or for the public health as there remains a risk of disease 
transmission. 
 
5.4) Conclusions and Recommendations 
 
In conclusion, the number of patients achieving HCV cure remains 
suboptimal, and the benefits of available and effective HCV therapies will not be 
realized unless effective measures are implemented for dealing with barriers to care. 
Our study findings suggest that emphasis should be placed on improving HCV 
treatment referrals and treatment eligibility, including development and 
implementation of referral and treatment protocols. More studies are clearly needed to 
explore ways to improve modifiable factors which have been identified as resulting in 
suboptimal HCV management outcomes. Future research should also focus on 
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defining the best candidates for treatment using cost effectiveness models based on 
real world data, and expanding care delivery models including those that support 
medication adherence in hard-to-treat populations such as substance users and 



























































































































































































































































































































































Appendix B: CDC Testing Recommendations for Hepatitis C Virus Infection 
 
Available at: http://www.cdc.gov/hepatitis/hcv/guidelinesc.htm 
 
CDC Testing Recommendations for Hepatitis C Virus Infection 
Testing should be initiated with anti-HCV. For those with reactive test results, the 
anti-HCV test should be followed with an HCV RNA. 
 
Persons for Whom HCV Testing Is Recommended 
• Adults born during 1945 through 1965 should be tested once (without prior 
ascertainment of HCV risk factors) 
• HCV-testing is recommended for those who: 
o Currently inject drugs 
o Ever injected drugs, including those who injected once or a few times 
many years ago 
o Have certain medical conditions, including persons: 
! who received clotting factor concentrates produced before 
1987 
! who were ever on long-term hemodialysis 
! with persistently abnormal alanine aminotransferase levels 
(ALT) 
! who have HIV infection 
o Were prior recipients of transfusions or organ transplants, including 
persons who: 
! were notified that they received blood from a donor who later 
tested positive for HCV infection 
! received a transfusion of blood, blood components or an organ 
transplant before July 1992  
• HCV- testing based on a recognized exposure is recommended for: 
o Healthcare, emergency medical, and public safety workers after needle 
sticks, sharps, or mucosal exposures to HCV-positive blood 
o Children born to HCV-positive women 
Note: For persons who might have been exposed to HCV within the past 6 months, 
testing for HCV RNA or follow-up testing for HCV antibody is recommended. 
  
Persons for Whom Routine HCV Testing is of uncertain need 
• Recipients of transplanted tissue (e.g., corneal, musculoskeletal, skin, ova, 
sperm) 
• Intranasal cocaine and other non-injecting illegal drug users 
• Persons with a history of tattooing or body piercing 
• Persons with a history of multiple sex partners or sexually transmitted 
diseases 
• Long-term steady sex partners of HCV-positive persons 
  
Persons for Whom Routine HCV Testing Is Not Recommended 
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(unless other risk factors present): 
• Health-care, emergency medical, and public safety workers 
• Pregnant women 
• Household (nonsexual) contacts of HCV-positive persons 





Appendix C: AASLD and IDSA Recommendations for Testing, Managing and 
Treating Hepatitis C 




Appendix D: Guidelines for the use of Antiretroviral Agents in HIV-1 infected Adults 





• All HIV-infected patients shold be screened for hepatitis C virus (HCV) infection. Patients at 
high risk of HCV should be screened annually and whenever HCV infection is suspected. 
• Antiretroviral therapy (ART) may slow the progression of liver disease by preserving or 
restoring immune function and reducing HIV-related immune activation and inflammation. 
For most HIV/HCV-coinfected patients, including those with cirrhosis, the benefits of ART 
outweigh concerns regarding drug-induced liver injury (DILI). Therefore, ART should be 
initiated in most HIV/HCV-coinfected patients, regardless of CD4 T lymphocyte (CD4) cell 
count (BII). 
• Initial ART combination regimens recommended for most HIV/HCV-coinfected patients are 
the same as those recommended for individuals without HCV infection. However, when 
treatment for both HIV and HCV is indicated, consideration of potential drug-drug 
interactions and overlapping toxicities should guide ART regimen selection or modification 
(see discussion in the text below and in Table 12). 
• Combined treatment of HIV and HCV can be complicated by drug-drug interactions, 
increased pill burden, and toxicities. Although ART should be initiated for most HIV/HCV-
coinfected patients regardless of CD4 cell count, in ART-naive patients with CD4 counts 
>500 cells/mm3 some clinicians may choose to defer ART until HCV treatment is 
completed (CIII). 
• In patients with lower CD4 counts (e.g., <200 cells/mm3), ART should be initiated 
expeditiously (AI) and HCV therapy may be delayed until the patient is stable on HIV 
treatment (CIII). 
Rating of Recommendations: A = Strong; B = Moderate; C = Optional 
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed 





Appendix E: Recommendations for Concomitant Use of Selected Antiretroviral 
Drugs and All Food and Drug Administration (FDA)-Approved Drugs for Treatment 
of Hepatitis C in HIV-Infected Adults 
 Available at: http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-
arv-guidelines/26/hiv-hcv 
 
Select ARV  
Drugs by Drug  
Class  
 HCV Drugs 





























Boceprevir  Telaprevir 
 (Discontinued 
from U.S. 
market in  
October 2014) 
Nucleoside Reverse Transcriptase Inhibitors 
 
FTC √ √ 
 





3TC √ √ √ √ √ √ √ 
ABC √ √ √ √ √ √ √ 
TDF √ √b √ √ √ 
Modify for 
TDF toxicity 
due to  
↑ TDF level. 
√ √ 
 ZDV √ √  √ Xa Xa Xa Xa 
 85 
 HIV Protease Inhibitors 
 ATV, ATV/r, or 
ATV/cobi 
√ √b  X X √ √ √ 
 DRV/r or DRV/cobi √ √b  X X X √ √ 
 FPV or FPV/r √ √b  X X X √  √  
 LPV/r √ √b  X X X 
 
√  √ 
 SQV/r √ √b  X X X 
 
√ √  
 TPV/r X 
 
X  X X X √ √  
 Non-Nucleoside Reverse Transcriptase Inhibitors 
 EFV √ √  
If EFV used  
with TDF/FTC, 
monitor 
for TDF toxicity due 
to 
↑ TDF level. 
X X √ 
↑ teleprevir 
dose to  
1125 mg q8h 
 
√ √ 














 √ √ √ 
 NVP √ √ X ? ? √ √ 
 
 RVP √ √ √ √ √ √ √ 
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 Integrase Strand Transfer Inhibitors 
 DTG √ √ √ √ √ √ √ 
 EVG/cobi/TDF/FTC √ X X X √ √ √ 
 EVG + (PI/r 
without cobi)  Refer to recommendations for specific ritonavir-boosted PI 
 RAL √ √ √ √ √ √ √ 
 CCR5 Antagonist 







dose to  
150 mg bid 
√ √ √ 
a Concomitant use of ZDV with boceprevir, telaprevir, or ribavirin is not recommended because of potential for 
worsening anemia; concomitant use with pegylated interferon is not recommended because of potential for 
worsening neutropenia. 
 
b Concomitant use of ledipasvir/sofosbuvir with TDF and an HIV PI/r (or ATV/cobi or DRV/cobi) may lead to 
increased TDF exposure; consider alternative HCV or ARV therapy, especially in patients at risk of renal injury. If 
co-administration is necessary, monitor for TDF-associated adverse reactions. 
 
 Key to Symbols: 
 √ = ARV agent and HCV drug that can be used concomitantly 
 ↑ = Increase  
 ↓ = Decrease 
 X = Concomitant use of the ARV agent and HCV drug is not recommended 
 ? = Data limited or not available on PK interactions between the ARV and HCV drugs 
Key to Acronyms: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; ATV/r = atazanavir/ritonavir; 
ATV/cobi = atazanavir/cobicistat; cobi = cobicistat; DRV/r = darunavir/ritonavir; DRV/cobi = darunavir/cobicistat; 
DTG = dolutegravir; EFV = efavirenz; ETR = etravirine; EVG = elvitegravir; FPV/r = fosamprenavir/ritonavir; 
FTC = emtricitabine; FDA = Food and Drug Administration; HCV = hepatitis C virus; HIV = human 
immunodeficiency virus; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; MVC = 
maraviroc; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase 
inhibitor; NVP = nevirapine; PI/r = ritonavir-boosted protease inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV 
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